<?php

namespace Database\Seeders;

use App\Models\EducationPost;
use App\Models\ProductCategory;
use Illuminate\Database\Seeder;

class EncyclopediaArticlesBatch1Seeder extends Seeder
{
    public function run(): void
    {
        $articles = $this->getArticles();

        foreach ($articles as $slug => $data) {
            $category = ProductCategory::where('slug', $slug)->first();
            if (!$category) {
                $this->command?->warn("Category not found: {$slug}");
                continue;
            }

            // Skip if already has a published article
            $existing = EducationPost::where('product_category_id', $category->id)
                ->where('status', 'published')
                ->first();
            if ($existing) {
                $this->command?->info("Skipping {$data['title']} — already has article");
                continue;
            }

            EducationPost::updateOrCreate(
                ['product_category_id' => $category->id],
                array_merge($data, [
                    'slug' => $slug,
                    'status' => 'published',
                    'published_at' => now(),
                    'storage' => 'Refrigerate at 2-8°C (36-46°F). Freeze lyophilized form for long-term storage.',
                ])
            );

            $this->command?->info("Created article: {$data['title']}");
        }
    }

    private function getArticles(): array
    {
        return [

            // ──────────────────────────────────────────────
            // 1. 5-Amino-1MQ
            // ──────────────────────────────────────────────
            '5-amino-1mq' => [
                'title' => '5-Amino-1MQ',
                'peptide_full_name' => '5-Amino-1-Methylquinolinium',
                'research_title' => '5-Amino-1MQ: A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of 5-Amino-1MQ, a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), examining its role in NAD+ biosynthesis modulation, metabolic research, and preclinical findings.',
                'education_tag' => 'Metabolic Research',
                'description' => '5-Amino-1MQ is a cell-permeable, small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in NAD+ metabolism and cellular energy homeostasis. By blocking NNMT activity, 5-Amino-1MQ increases intracellular NAD+ levels and modulates metabolic pathways linked to adipogenesis and energy expenditure.',
                'molecular_formula' => 'C₁₀H₁₁N₂O⁺',
                'molecular_weight' => '175.21 g/mol',
                'half_life' => 'Not fully characterized (small molecule, estimated hours)',
                'bioavailability' => 'Oral and parenteral (cell-permeable small molecule)',
                'background' => 'Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). NNMT sits at the intersection of NAD+ salvage and methyl donor metabolism, making it a critical regulator of cellular energy balance. NNMT expression is elevated in adipose tissue of obese and diabetic individuals, and its overexpression has been linked to increased fat deposition and metabolic dysfunction. 5-Amino-1MQ was developed as a selective, cell-permeable inhibitor of NNMT. Preclinical research has demonstrated that NNMT inhibition with 5-Amino-1MQ can reduce adipocyte size, increase intracellular NAD+ concentrations, and promote a favorable shift in cellular energy metabolism. The compound has garnered research interest as a potential tool for studying the metabolic consequences of NNMT inhibition, particularly in models of obesity, type 2 diabetes, and age-related metabolic decline. Unlike many peptide-based research compounds, 5-Amino-1MQ is a small molecule with favorable cell permeability properties.',
                'mechanism_of_action_intro' => '5-Amino-1MQ exerts its effects by selectively inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme that diverts nicotinamide away from the NAD+ salvage pathway. Blocking NNMT redirects nicotinamide toward NAD+ biosynthesis.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'NNMT inhibition by 5-Amino-1MQ produces several downstream metabolic effects through modulation of the NAD+/SAM metabolic nexus.',
                        'points' => [
                            'Selectively inhibits NNMT, preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA)',
                            'Increases intracellular NAD+ levels by redirecting nicotinamide into the NAD+ salvage pathway via NAMPT',
                            'Preserves SAM (S-adenosylmethionine) methyl donor pools by reducing NNMT-mediated consumption',
                            'Activates SIRT1-dependent signaling pathways downstream of increased NAD+ availability',
                            'Reduces expression of adipogenic transcription factors including PPARγ and C/EBPα in preclinical models',
                        ],
                    ],
                ]),
                'preclinical_intro' => '5-Amino-1MQ has been studied primarily in cell culture systems and rodent models of metabolic disease, with findings centered on adipocyte biology and energy metabolism.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Adipocyte and Metabolic Research',
                        'findings' => [
                            ['title' => 'Adipocyte Size Reduction', 'description' => 'In diet-induced obesity (DIO) mouse models, treatment with 5-Amino-1MQ significantly reduced white adipocyte size and total body fat mass without affecting food intake, suggesting a direct metabolic rather than anorectic mechanism of action.'],
                            ['title' => 'NAD+ Elevation', 'description' => 'Cell culture studies demonstrate that NNMT inhibition with 5-Amino-1MQ increases intracellular NAD+ concentrations, which activates NAD+-dependent enzymes including sirtuins involved in metabolic regulation.'],
                            ['title' => 'Cholesterol Metabolism', 'description' => 'Preclinical data suggest that NNMT inhibition may reduce total plasma cholesterol levels in DIO models, potentially through modulation of hepatic lipid metabolism pathways.'],
                        ],
                    ],
                    [
                        'title' => 'Cellular Energy Metabolism',
                        'findings' => [
                            ['title' => 'Mitochondrial Function', 'description' => 'In vitro studies indicate that increased NAD+ availability following NNMT inhibition enhances mitochondrial oxidative phosphorylation and shifts cellular metabolism toward increased energy expenditure.'],
                            ['title' => 'Stem Cell Differentiation', 'description' => 'Research in mesenchymal stem cell models shows that NNMT inhibition alters the differentiation bias away from adipogenesis and may influence osteogenic lineage commitment.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from cell culture and animal models. 5-Amino-1MQ has not been evaluated in human clinical trials. Preclinical metabolic effects may not translate directly to human outcomes.',
                'human_use_intro' => 'No published human clinical trials exist for 5-Amino-1MQ. All current evidence is derived from in-vitro and animal model research. The compound remains in the preclinical investigation stage.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => '5-Amino-1MQ has not undergone formal human clinical trials. While NNMT has been identified as a target of interest in human metabolic disease, the specific pharmacokinetics, safety profile, and efficacy of 5-Amino-1MQ in humans remain uncharacterized.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => '5-Amino-1MQ is not approved by the FDA, EMA, or any regulatory body for human therapeutic use. It is classified as a research chemical available exclusively for in-vitro and preclinical research purposes.'], ['type' => 'content', 'value' => 'As a small-molecule NNMT inhibitor, 5-Amino-1MQ falls outside the peptide hormone categories monitored by WADA, though its regulatory classification in sports contexts has not been formally addressed.']]]]),
                'regulatory_important_note' => '5-Amino-1MQ is an experimental research compound. It is not approved for human consumption, therapeutic use, or self-administration. All research must comply with applicable institutional and regulatory guidelines.',
                'potential_applications_intro' => 'Based on preclinical evidence, 5-Amino-1MQ has generated research interest in several metabolic and aging-related domains.',
                'potential_applications' => json_encode([
                    ['title' => 'Obesity and Adipose Biology Research', 'description' => 'NNMT inhibition offers a novel approach to studying adipocyte metabolism, fat mass regulation, and the role of NAD+ in adipose tissue homeostasis.'],
                    ['title' => 'NAD+ Biology and Aging Research', 'description' => 'As a tool for elevating intracellular NAD+ levels, 5-Amino-1MQ is relevant to research on sirtuin biology, mitochondrial function, and age-related metabolic decline.'],
                    ['title' => 'Metabolic Syndrome Modeling', 'description' => 'Preclinical effects on body composition and cholesterol suggest utility in research models of metabolic syndrome and insulin resistance.'],
                ]),
                'potential_applications_important_context' => 'All potential applications are based on preclinical research. No therapeutic claims are made. Human efficacy and safety have not been established.',
                'conclusion' => '5-Amino-1MQ represents an emerging tool in metabolic research, offering a targeted approach to studying the consequences of NNMT inhibition on cellular energy balance, NAD+ metabolism, and adipocyte biology. Preclinical data in diet-induced obesity models have demonstrated meaningful effects on adipocyte size, body fat mass, and cholesterol levels without affecting food intake, suggesting a mechanism distinct from traditional anorectic compounds. The compound\'s position at the intersection of NAD+ salvage and methyl donor metabolism makes it relevant to broader research on aging, sirtuin biology, and metabolic disease. However, 5-Amino-1MQ remains entirely in the preclinical stage. No human clinical trials have been conducted, and the compound\'s pharmacokinetic profile, long-term safety, and therapeutic potential in humans are unknown. Researchers interested in NNMT as a metabolic target continue to use 5-Amino-1MQ as a valuable pharmacological tool in controlled laboratory settings.',
                'references' => json_encode([
                    ['title' => 'Nature (2014)', 'authors' => 'Kraus D et al.', 'links' => []],
                    ['title' => 'Biochemical Pharmacology (2020)', 'authors' => 'Neelakantan H et al.', 'links' => []],
                    ['title' => 'Journal of Pharmacology and Experimental Therapeutics (2018)', 'authors' => 'Neelakantan H et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT)', 'Increases intracellular NAD+ by redirecting nicotinamide into the salvage pathway', 'Preclinical studies show reduced adipocyte size and body fat in DIO models', 'Not approved for human use — classified as research use only (RUO)']),
                'overview' => '5-Amino-1MQ is a cell-permeable NNMT inhibitor that modulates NAD+ biosynthesis and has shown metabolic effects in preclinical obesity research.',
                'areas_of_research_intro' => '5-Amino-1MQ is investigated in metabolic, aging, and adipose biology research contexts.',
                'areas_of_research' => json_encode([
                    ['name' => 'Metabolic Research', 'description' => 'NNMT inhibition, NAD+ modulation, and energy expenditure'],
                    ['name' => 'Adipose Biology', 'description' => 'Adipogenesis, adipocyte size regulation, and fat mass reduction'],
                    ['name' => 'Aging Research', 'description' => 'NAD+ decline, sirtuin activation, and mitochondrial function'],
                ]),
                'key_effects' => json_encode(['Selective NNMT inhibition', 'Increased intracellular NAD+ levels', 'Reduced adipocyte size in preclinical models', 'Modulates SAM/methyl donor metabolism']),
                'common_use_cases' => json_encode(['NNMT pathway research', 'NAD+ metabolism studies', 'Obesity model investigations']),
                'how_it_works' => '5-Amino-1MQ selectively inhibits NNMT, preventing the methylation of nicotinamide to 1-MNA. This redirects nicotinamide into the NAD+ salvage pathway via NAMPT, increasing intracellular NAD+ levels and activating NAD+-dependent enzymes such as SIRT1. Simultaneously, it preserves SAM methyl donor pools.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 2. HCG (Human Chorionic Gonadotropin)
            // ──────────────────────────────────────────────
            'hcg' => [
                'title' => 'HCG (Human Chorionic Gonadotropin)',
                'peptide_full_name' => 'Human Chorionic Gonadotropin',
                'research_title' => 'HCG (Human Chorionic Gonadotropin): A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of human chorionic gonadotropin (hCG), a glycoprotein hormone central to reproductive biology, examining its structure, receptor pharmacology, clinical applications, and research significance.',
                'education_tag' => 'Reproductive Health',
                'description' => 'Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein hormone composed of an alpha subunit shared with LH, FSH, and TSH, and a unique beta subunit that confers biological specificity. Produced primarily by placental trophoblast cells, hCG signals through the LH/CG receptor to support corpus luteum function and steroidogenesis.',
                'molecular_formula' => 'Glycoprotein (~237 amino acids, heterodimer)',
                'molecular_weight' => '~36,700 g/mol',
                'half_life' => '24-36 hours',
                'bioavailability' => 'Parenteral administration (intramuscular or subcutaneous)',
                'background' => 'Human chorionic gonadotropin (hCG) is a glycoprotein hormone first identified in the 1920s as a substance produced by the placenta during pregnancy. It is composed of two non-covalently linked subunits: an alpha subunit (92 amino acids) identical to that of LH, FSH, and TSH, and a beta subunit (145 amino acids) unique to hCG that determines its receptor specificity and immunological identity. The beta subunit shares approximately 85% sequence homology with LH-beta but contains a C-terminal extension of 24 amino acids rich in serine residues that are heavily O-glycosylated, contributing to hCG\'s longer circulating half-life compared to LH. hCG is the earliest endocrine signal of implantation, produced by syncytiotrophoblast cells as early as 6-8 days post-fertilization. Its primary physiological role is to maintain the corpus luteum and sustain progesterone production during early pregnancy until the placenta assumes steroidogenic autonomy. Beyond reproduction, hCG signals through the LH/CG receptor (LHCGR) expressed on Leydig cells, ovarian theca and granulosa cells, and various extragonadal tissues. Pharmaceutical preparations include urinary-derived (uhCG) and recombinant (rhCG) forms used in fertility medicine.',
                'mechanism_of_action_intro' => 'hCG exerts its biological effects by binding to the luteinizing hormone/choriogonadotropin receptor (LHCGR), a G-protein coupled receptor expressed on gonadal and various extragonadal tissues.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'LHCGR activation by hCG initiates multiple intracellular signaling cascades that regulate steroidogenesis, cell differentiation, and tissue remodeling.',
                        'points' => [
                            'Binds LHCGR with high affinity, activating Gs-coupled adenylyl cyclase and increasing intracellular cAMP',
                            'cAMP-dependent PKA activation stimulates steroidogenic acute regulatory protein (StAR) expression, promoting cholesterol transport to mitochondria for steroid synthesis',
                            'Activates MAPK/ERK signaling in certain cell types, contributing to proliferative and differentiative effects',
                            'In Leydig cells, stimulates testosterone biosynthesis through upregulation of steroidogenic enzymes (CYP11A1, CYP17A1, 3β-HSD)',
                            'Longer half-life than LH (24-36h vs 20 min) due to additional glycosylation, providing more sustained receptor activation',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'hCG has been extensively studied in reproductive biology, with a research history spanning nearly a century across both animal models and human clinical settings.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Reproductive Biology Research',
                        'findings' => [
                            ['title' => 'Leydig Cell Stimulation', 'description' => 'In male animal models and testicular tissue cultures, hCG reliably stimulates Leydig cell testosterone production in a dose-dependent manner, making it a standard tool for assessing testicular steroidogenic capacity.'],
                            ['title' => 'Ovarian Physiology', 'description' => 'hCG is used experimentally to trigger oocyte maturation and ovulation in animal models, mimicking the endogenous LH surge. It has been instrumental in understanding follicular dynamics and luteinization.'],
                        ],
                    ],
                    [
                        'title' => 'Extragonadal Research',
                        'findings' => [
                            ['title' => 'Angiogenesis Studies', 'description' => 'Research has identified pro-angiogenic properties of hCG mediated through VEGF upregulation, with relevance to implantation biology and tumor vasculature research.'],
                            ['title' => 'Immunomodulation', 'description' => 'Preclinical evidence suggests hCG may modulate immune tolerance mechanisms, a finding with relevance to understanding maternal-fetal immune adaptation during pregnancy.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'While hCG has extensive clinical use in pharmaceutical form, research-grade hCG products are intended solely for laboratory investigation. Preclinical findings in extragonadal contexts require further clinical validation.',
                'human_use_intro' => 'Pharmaceutical hCG has a long clinical history and is FDA-approved for specific reproductive indications in both males and females.',
                'human_use_subsections' => json_encode([
                    [
                        'title' => 'Approved Clinical Uses',
                        'entries' => [
                            ['type' => 'content', 'value' => 'hCG is FDA-approved for the treatment of prepubertal cryptorchidism (not due to anatomical obstruction), for induction of ovulation in anovulatory infertility (in conjunction with FSH preparations), and for the treatment of select cases of male hypogonadotropic hypogonadism.'],
                            ['type' => 'content', 'value' => 'In assisted reproductive technology (ART), recombinant hCG (Ovidrel) is widely used as a trigger for final oocyte maturation prior to retrieval, replacing the endogenous LH surge.'],
                        ],
                    ],
                    [
                        'title' => 'Clinical Research Applications',
                        'entries' => [
                            ['type' => 'content', 'value' => 'hCG stimulation testing is used clinically to assess Leydig cell function and testicular reserve in males with suspected hypogonadism. A rise in testosterone following hCG administration confirms functional testicular tissue.'],
                            ['type' => 'content', 'value' => 'Clinical studies have investigated hCG as an adjunct to testosterone replacement therapy to maintain intratesticular testosterone levels and preserve spermatogenesis.'],
                        ],
                    ],
                ]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Pharmaceutical hCG preparations (Pregnyl, Novarel, Ovidrel) are FDA-approved for specific reproductive indications. However, research-grade hCG is not equivalent to pharmaceutical preparations and is sold strictly for laboratory use only (RUO).'], ['type' => 'content', 'value' => 'hCG is a controlled substance in some jurisdictions and is prohibited by WADA in male athletes as an LH mimetic that can stimulate endogenous testosterone production.']]]]),
                'regulatory_important_note' => 'Research-grade hCG is not equivalent to pharmaceutical hCG. It is sold for laboratory research purposes only and is not intended for human therapeutic use or self-administration.',
                'potential_applications_intro' => 'Based on extensive clinical and preclinical evidence, hCG research spans multiple domains of reproductive and developmental biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Reproductive Endocrinology Research', 'description' => 'hCG remains a fundamental tool for studying gonadal steroidogenesis, oocyte maturation, and HPG axis physiology in research settings.'],
                    ['title' => 'Testicular Function Assessment', 'description' => 'hCG stimulation protocols are used in research to evaluate Leydig cell reserve and characterize steroidogenic enzyme activity.'],
                    ['title' => 'Implantation and Early Pregnancy Biology', 'description' => 'Research continues into hCG\'s roles in endometrial receptivity, trophoblast invasion, and immune tolerance during the implantation window.'],
                ]),
                'potential_applications_important_context' => 'Research-grade hCG is for laboratory investigation only. Approved clinical applications require pharmaceutical-grade preparations prescribed and supervised by qualified physicians.',
                'conclusion' => 'Human chorionic gonadotropin is one of the most well-characterized hormones in reproductive medicine, with a research and clinical history spanning nearly a century. Its unique structure, featuring a beta subunit with extended glycosylation that confers both immunological specificity and prolonged biological activity, has made it an essential diagnostic marker and therapeutic agent in reproductive endocrinology. Pharmaceutical hCG preparations are FDA-approved for specific fertility and hypogonadism indications, while the hormone continues to serve as a critical research tool for investigating gonadal function, steroidogenesis, and early pregnancy biology. Emerging research into extragonadal LHCGR expression and hCG\'s roles in angiogenesis and immunomodulation may open new investigational avenues. Research-grade hCG products remain strictly for laboratory use and are not equivalent to approved pharmaceutical formulations.',
                'references' => json_encode([
                    ['title' => 'Endocrine Reviews (2010)', 'authors' => 'Cole LA.', 'links' => []],
                    ['title' => 'Molecular and Cellular Endocrinology (2007)', 'authors' => 'Ascoli M et al.', 'links' => []],
                    ['title' => 'New England Journal of Medicine (2001)', 'authors' => 'Stenman UH et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['hCG is a heterodimeric glycoprotein hormone with a unique beta subunit', 'Signals through the LH/CG receptor to stimulate steroidogenesis', 'FDA-approved pharmaceutical forms exist for specific reproductive indications', 'Research-grade products are for laboratory use only (RUO)']),
                'overview' => 'Human chorionic gonadotropin (hCG) is a glycoprotein hormone that signals through the LH/CG receptor, central to reproductive endocrinology and fertility research.',
                'areas_of_research_intro' => 'hCG research spans reproductive endocrinology, fertility medicine, and developmental biology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Reproductive Endocrinology', 'description' => 'Gonadal steroidogenesis and HPG axis regulation'],
                    ['name' => 'Fertility Research', 'description' => 'Oocyte maturation, ovulation induction, and ART protocols'],
                    ['name' => 'Developmental Biology', 'description' => 'Implantation biology and early pregnancy signaling'],
                ]),
                'key_effects' => json_encode(['Stimulates testosterone production via Leydig cells', 'Triggers oocyte maturation and ovulation', 'Maintains corpus luteum function', 'Long half-life (24-36h) vs LH']),
                'common_use_cases' => json_encode(['Reproductive biology research', 'Steroidogenesis studies', 'Gonadal function assessment']),
                'how_it_works' => 'hCG binds the LH/CG receptor (LHCGR) on gonadal cells, activating Gs-coupled adenylyl cyclase signaling. This increases intracellular cAMP, activating PKA, which upregulates StAR protein and steroidogenic enzymes to promote testosterone or progesterone synthesis depending on cell type.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 3. Humanin
            // ──────────────────────────────────────────────
            'humanin' => [
                'title' => 'Humanin',
                'peptide_full_name' => 'Humanin (HN)',
                'research_title' => 'Humanin: A Comprehensive Research Overview',
                'research_outline' => 'An in-depth examination of Humanin, a mitochondria-derived peptide (MDP) with cytoprotective and metabolic regulatory properties, covering its discovery, mechanism of action, preclinical findings in aging and neurodegeneration, and current research status.',
                'education_tag' => 'Aging Research',
                'description' => 'Humanin is a 24-amino acid peptide encoded within the mitochondrial 16S ribosomal RNA gene (MT-RNR2). It was the first identified member of the mitochondria-derived peptide (MDP) family and exhibits potent cytoprotective effects against apoptosis, oxidative stress, and mitochondrial dysfunction in preclinical models.',
                'molecular_formula' => 'C₁₁₈H₁₉₇N₃₃O₃₂S₂',
                'molecular_weight' => '2,687.2 g/mol',
                'half_life' => 'Minutes to hours (variable by analog; native form rapidly degraded)',
                'bioavailability' => 'Parenteral (native peptide subject to rapid proteolysis)',
                'background' => 'Humanin was discovered in 2001 by Nishimoto and colleagues through a functional screening for genes that could rescue neuronal cells from death induced by familial Alzheimer\'s disease mutant proteins. Remarkably, the protective cDNA mapped to the mitochondrial genome — specifically the 16S ribosomal RNA gene (MT-RNR2) — making Humanin the first identified mitochondria-derived peptide (MDP). This discovery established a new paradigm: mitochondria as sources of bioactive signaling peptides with endocrine and paracrine functions. The native 24-amino acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) circulates in plasma and cerebrospinal fluid, with levels declining with age. Humanin signals through multiple receptor systems including FPRL1 (formyl peptide receptor-like 1), the CNTFR/WSX-1/gp130 tripartite receptor complex, and directly interacts with pro-apoptotic Bax and IGFBP-3. Modified analogs such as HNG (S14G-Humanin) exhibit 1000-fold greater potency. Humanin research has expanded rapidly, linking this MDP to neuroprotection, metabolic regulation, cardiovascular protection, and the biology of aging.',
                'mechanism_of_action_intro' => 'Humanin exerts cytoprotective effects through both intracellular and extracellular mechanisms, engaging multiple signaling pathways to inhibit apoptosis and promote cellular survival.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'Humanin signals through at least three distinct receptor/binding partner systems, each contributing to its broad cytoprotective profile.',
                        'points' => [
                            'Binds the tripartite receptor complex (CNTFR/WSX-1/gp130), activating JAK2/STAT3 signaling to promote cell survival and suppress apoptosis',
                            'Interacts directly with pro-apoptotic Bax protein, preventing Bax translocation to mitochondria and blocking the intrinsic apoptotic cascade',
                            'Binds IGFBP-3, antagonizing IGFBP-3-mediated apoptosis and modulating IGF signaling dynamics',
                            'Activates FPRL1 (formyl peptide receptor-like 1), triggering ERK1/2 and Akt phosphorylation for anti-apoptotic signaling',
                            'Enhances mitochondrial respiration and reduces reactive oxygen species (ROS) production in stressed cells',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Humanin has been extensively studied in cell culture and animal models, with preclinical evidence spanning neurodegeneration, metabolic disease, cardiovascular protection, and aging.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Neuroprotection Research',
                        'findings' => [
                            ['title' => 'Alzheimer\'s Disease Models', 'description' => 'Humanin and its more potent analog HNG (S14G-Humanin) have demonstrated neuroprotective effects against amyloid-beta toxicity in neuronal cell cultures and in transgenic AD mouse models, reducing neuronal death and cognitive decline markers.'],
                            ['title' => 'Stroke and Ischemia Models', 'description' => 'In rodent cerebral ischemia-reperfusion models, Humanin administration reduced infarct volume and improved functional outcomes, attributed to its anti-apoptotic and ROS-scavenging properties.'],
                        ],
                    ],
                    [
                        'title' => 'Metabolic and Aging Research',
                        'findings' => [
                            ['title' => 'Insulin Sensitivity', 'description' => 'Studies in HFD (high-fat diet) mouse models show that Humanin analog administration improves insulin sensitivity, reduces hepatic glucose production, and ameliorates diet-induced metabolic dysfunction through central and peripheral mechanisms.'],
                            ['title' => 'Age-Related Decline', 'description' => 'Circulating Humanin levels decline with age in humans and animal models. In long-lived species and centenarian cohorts, relatively preserved Humanin levels have been observed, suggesting a correlation between MDP levels and longevity.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from cell culture and animal models. Humanin and its analogs have not been evaluated in human clinical trials for therapeutic efficacy. Preclinical observations may not translate to human clinical outcomes.',
                'human_use_intro' => 'No formal human clinical trials have been conducted with exogenous Humanin administration. Human data is limited to observational studies measuring endogenous circulating Humanin levels in various populations.',
                'human_use_subsections' => json_encode([['title' => 'Human Observational Data', 'entries' => [['type' => 'content', 'value' => 'Epidemiological studies have measured circulating Humanin levels in human cohorts, finding that plasma Humanin declines with age and is relatively preserved in centenarians and their offspring compared to age-matched controls.'], ['type' => 'content', 'value' => 'Lower circulating Humanin levels have been associated with Alzheimer\'s disease, type 2 diabetes, and cardiovascular disease in observational studies, though causality has not been established.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Humanin is not approved by the FDA, EMA, or any regulatory body for human therapeutic use. It is available as a research peptide for in-vitro and preclinical investigation only.'], ['type' => 'content', 'value' => 'No IND (Investigational New Drug) applications for Humanin or its analogs are publicly registered as of current knowledge.']]]]),
                'regulatory_important_note' => 'Humanin is an experimental research peptide. It is not approved for human consumption, therapeutic use, or self-administration. All research must comply with applicable regulatory frameworks.',
                'potential_applications_intro' => 'Preclinical evidence has identified several research domains where Humanin and its analogs may serve as valuable investigational tools.',
                'potential_applications' => json_encode([
                    ['title' => 'Neurodegeneration Research', 'description' => 'Humanin\'s protective effects against amyloid-beta and ischemic neuronal death make it relevant for Alzheimer\'s, stroke, and broader neuroprotection research.'],
                    ['title' => 'Aging and Longevity Research', 'description' => 'As a mitochondria-derived peptide that declines with age, Humanin is a focus of geroscience research into mitochondrial signaling and healthspan.'],
                    ['title' => 'Metabolic Disease Research', 'description' => 'Preclinical insulin-sensitizing effects position Humanin as a tool for studying metabolic regulation and type 2 diabetes pathophysiology.'],
                    ['title' => 'Mitochondrial Biology', 'description' => 'As the founding member of the MDP family, Humanin is central to understanding how mitochondrial-encoded peptides function as retrograde signaling molecules.'],
                ]),
                'potential_applications_important_context' => 'All potential applications are based on preclinical and observational research. No therapeutic claims are made. Clinical efficacy and safety have not been established.',
                'conclusion' => 'Humanin occupies a pioneering position in the emerging field of mitochondria-derived peptides (MDPs). Its discovery in 2001 established that the mitochondrial genome encodes bioactive signaling molecules with endocrine functions beyond oxidative phosphorylation. Preclinical research has consistently demonstrated Humanin\'s cytoprotective properties — protecting against apoptosis, oxidative stress, and metabolic dysfunction across neuronal, cardiovascular, and metabolic models. The observation that circulating Humanin levels decline with age and are relatively preserved in exceptionally long-lived individuals adds an intriguing correlative dimension to aging research. However, Humanin remains entirely in the preclinical and observational stage. No human interventional trials have been conducted, and fundamental questions about pharmacokinetics, optimal analogs, and long-term safety in humans remain unanswered. Humanin continues to be a valuable research tool for investigating mitochondrial retrograde signaling, cytoprotective mechanisms, and the biology of aging.',
                'references' => json_encode([
                    ['title' => 'Proceedings of the National Academy of Sciences (2001)', 'authors' => 'Hashimoto Y et al.', 'links' => []],
                    ['title' => 'Aging Cell (2013)', 'authors' => 'Muzumdar RH et al.', 'links' => []],
                    ['title' => 'Cell Metabolism (2018)', 'authors' => 'Kim SJ et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Humanin is a 24-amino acid mitochondria-derived peptide encoded by MT-RNR2', 'Exerts cytoprotective effects through STAT3, Bax inhibition, and FPRL1 signaling', 'Circulating levels decline with age and are preserved in centenarians', 'Not approved for human use — classified as research use only (RUO)']),
                'overview' => 'Humanin is a mitochondria-derived peptide with broad cytoprotective properties, central to aging, neuroprotection, and metabolic regulation research.',
                'areas_of_research_intro' => 'Humanin research spans neuroscience, geroscience, metabolic disease, and fundamental mitochondrial biology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Neuroscience', 'description' => 'Neuroprotection against amyloid-beta and ischemic injury'],
                    ['name' => 'Geroscience', 'description' => 'Mitochondrial peptides, aging biomarkers, and longevity correlates'],
                    ['name' => 'Metabolic Research', 'description' => 'Insulin sensitivity and glucose homeostasis'],
                ]),
                'key_effects' => json_encode(['Anti-apoptotic cytoprotection', 'Mitochondrial function enhancement', 'Neuroprotective in preclinical models', 'Insulin-sensitizing properties']),
                'common_use_cases' => json_encode(['Mitochondria-derived peptide research', 'Neuroprotection studies', 'Aging biomarker investigations']),
                'how_it_works' => 'Humanin binds the CNTFR/WSX-1/gp130 tripartite receptor to activate JAK2/STAT3 survival signaling, directly sequesters pro-apoptotic Bax to prevent mitochondrial outer membrane permeabilization, and engages FPRL1 to activate ERK1/2 and Akt anti-apoptotic pathways.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 4. Thymalin
            // ──────────────────────────────────────────────
            'thymalin' => [
                'title' => 'Thymalin',
                'peptide_full_name' => 'Thymalin (Thymic Peptide Complex)',
                'research_title' => 'Thymalin: A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of Thymalin, a thymic-derived peptide bioregulator developed in the Khavinson school of peptide bioregulation, covering its immunomodulatory mechanisms, preclinical and clinical research in aging and immune function, and regulatory context.',
                'education_tag' => 'Immune Modulation',
                'description' => 'Thymalin is a polypeptide complex originally isolated from bovine thymus gland by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the class of Khavinson peptide bioregulators and has been investigated for its effects on immune reconstitution, thymic function, and age-related immunosenescence.',
                'molecular_formula' => 'Polypeptide complex (multiple low-MW peptides)',
                'molecular_weight' => '~1,000-10,000 g/mol (mixture)',
                'half_life' => 'Not precisely characterized (polypeptide complex)',
                'bioavailability' => 'Parenteral administration (intramuscular)',
                'background' => 'Thymalin was developed in the 1970s by Professor Vladimir Khavinson at the Military Medical Academy in St. Petersburg (then Leningrad), Russia, as part of a broader research program on peptide bioregulators — short peptides derived from organ-specific tissues that were hypothesized to regulate gene expression and restore physiological function in the tissues of origin. Thymalin is extracted from the thymus glands of young calves and contains a complex of low-molecular-weight peptides that collectively modulate immune function. The thymus gland is central to T-cell maturation and immune competence, and its involution with age is a major driver of immunosenescence. Khavinson\'s research group has published extensively on Thymalin in Russian and international journals, reporting effects on T-cell differentiation, immune reconstitution in immunodeficient states, and lifespan extension in animal models. Thymalin has been registered and used clinically in Russia for immune deficiency conditions, though it has not been approved by Western regulatory agencies. The compound represents the broader Khavinson approach of using tissue-specific peptides as "bioregulators" to restore age-related functional decline.',
                'mechanism_of_action_intro' => 'Thymalin is proposed to act through modulation of thymic microenvironment signaling and T-cell differentiation pathways. As a complex mixture rather than a single peptide, its mechanism is attributed to the collective actions of its constituent peptides.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The proposed mechanisms of Thymalin involve restoration of thymic function and immune cell homeostasis through peptide-mediated gene regulation.',
                        'points' => [
                            'Contains thymic peptides proposed to interact with chromatin and modulate gene expression in immunocompetent cells',
                            'Reported to promote differentiation and maturation of T-lymphocyte precursors, increasing mature T-cell populations',
                            'May modulate CD4/CD8 T-cell ratios and restore age-related imbalances in T-helper/T-suppressor cell populations',
                            'Proposed to influence thymic epithelial cell function and thymic microenvironment signaling (thymopoiesis)',
                            'Reported epigenetic effects on gene expression patterns associated with immune function and stress response',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Thymalin has been studied in animal models and in Russian clinical settings, with a body of literature primarily published in Russian-language journals and selectively in international publications.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Animal Longevity and Aging Studies',
                        'findings' => [
                            ['title' => 'Lifespan Studies', 'description' => 'In studies conducted by Khavinson\'s group, Thymalin administration to aging rodents and non-human primates was reported to extend mean lifespan by 20-40%, with improvements in immune function biomarkers. These findings have been published in Bulletin of Experimental Biology and Medicine and other journals.'],
                            ['title' => 'Immunosenescence Models', 'description' => 'In aged rodent models, Thymalin administration was associated with partial restoration of thymic architecture, increased T-cell counts, and improved responses to immunological challenge.'],
                        ],
                    ],
                    [
                        'title' => 'Immune Function Research',
                        'findings' => [
                            ['title' => 'T-Cell Differentiation', 'description' => 'In vitro and in vivo studies report that Thymalin peptides promote the differentiation of pre-T cells into mature CD3+, CD4+, and CD8+ T-lymphocytes, suggesting a direct effect on thymopoiesis.'],
                            ['title' => 'Post-Surgical Immune Recovery', 'description' => 'Russian clinical studies have investigated Thymalin for immune reconstitution following surgery, radiation therapy, and in immunodeficiency states, reporting accelerated recovery of lymphocyte counts and function.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Much of the published research on Thymalin originates from the Khavinson group and Russian institutions. Independent replication by Western laboratories is limited. Results should be interpreted in this context.',
                'human_use_intro' => 'Thymalin has been used clinically in Russia and some former Soviet states for immune deficiency conditions. However, it has not undergone clinical trials meeting Western regulatory standards (ICH-GCP).',
                'human_use_subsections' => json_encode([['title' => 'Clinical Experience', 'entries' => [['type' => 'content', 'value' => 'Thymalin has been registered and used in Russian clinical practice for conditions including post-surgical immunodeficiency, radiation-induced immune suppression, and age-related immune decline. Published Russian clinical data report improvements in T-cell counts and immune function parameters.'], ['type' => 'content', 'value' => 'A long-term observational study by Khavinson and colleagues reported that elderly patients receiving Thymalin courses showed reduced mortality rates and improved immune biomarkers over multi-year follow-up periods, though these studies were not randomized controlled trials by Western standards.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Thymalin is registered as a pharmaceutical product in Russia for immune modulation. It is not approved by the FDA, EMA, or other Western regulatory agencies, and has not undergone ICH-GCP compliant clinical trials.'], ['type' => 'content', 'value' => 'Outside of Russia, Thymalin is available only as a research peptide for laboratory investigation. It is not approved for human therapeutic use in Western jurisdictions.']]]]),
                'regulatory_important_note' => 'Thymalin is not approved by Western regulatory agencies. Research-grade Thymalin is sold for laboratory investigation only and is not intended for human therapeutic use or self-administration.',
                'potential_applications_intro' => 'Based on published preclinical and Russian clinical literature, Thymalin research centers on immunosenescence and aging biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Immunosenescence Research', 'description' => 'Thymalin is investigated as a tool for studying age-related thymic involution and the potential for immune reconstitution through peptide bioregulation.'],
                    ['title' => 'Aging and Longevity Research', 'description' => 'Animal lifespan extension data have generated interest in Thymalin within the context of Khavinson\'s peptide bioregulation hypothesis of aging.'],
                    ['title' => 'Peptide Bioregulation Studies', 'description' => 'Thymalin exemplifies the Khavinson approach to tissue-specific peptide bioregulators and serves as a research tool for investigating epigenetic peptide effects on gene expression.'],
                ]),
                'potential_applications_important_context' => 'All potential applications outside of Russian clinical practice are investigational. Western clinical validation is lacking. No therapeutic claims are made for research-grade products.',
                'conclusion' => 'Thymalin represents a distinctive approach to immunomodulation and aging research rooted in the Khavinson school of peptide bioregulation. Developed from thymic tissue extracts, it has accumulated a substantial body of literature — primarily from Russian institutions — supporting effects on immune reconstitution, T-cell maturation, and potentially lifespan extension. While registered for clinical use in Russia, Thymalin has not undergone clinical trials meeting Western regulatory standards, and independent replication of key findings by non-affiliated laboratories remains limited. The compound occupies an interesting position at the intersection of thymic biology, immunosenescence, and the broader hypothesis that tissue-derived short peptides can serve as epigenetic regulators of organ-specific gene expression. Researchers outside of Russia should approach Thymalin literature with awareness of its predominantly single-group provenance while recognizing the legitimate scientific questions it raises about thymic peptides and immune aging.',
                'references' => json_encode([
                    ['title' => 'Bulletin of Experimental Biology and Medicine (2003)', 'authors' => 'Khavinson VKh, Morozov VG.', 'links' => []],
                    ['title' => 'Neuroendocrinology Letters (2003)', 'authors' => 'Khavinson VKh.', 'links' => []],
                    ['title' => 'Advances in Gerontology (2010)', 'authors' => 'Khavinson VKh et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Thymalin is a polypeptide complex derived from bovine thymus tissue', 'Investigated for immune reconstitution and T-cell maturation in aging', 'Registered for clinical use in Russia but not approved by Western regulatory agencies', 'Research-grade products are for laboratory use only (RUO)']),
                'overview' => 'Thymalin is a thymic peptide bioregulator investigated for immunomodulation, immune reconstitution, and aging research within the Khavinson bioregulation framework.',
                'areas_of_research_intro' => 'Thymalin research centers on immunology, aging biology, and peptide bioregulation.',
                'areas_of_research' => json_encode([
                    ['name' => 'Immunology', 'description' => 'T-cell differentiation, immune reconstitution, and thymic function'],
                    ['name' => 'Gerontology', 'description' => 'Immunosenescence, lifespan extension, and age-related immune decline'],
                    ['name' => 'Peptide Bioregulation', 'description' => 'Tissue-specific peptide effects on gene expression and epigenetic regulation'],
                ]),
                'key_effects' => json_encode(['T-cell maturation promotion', 'Immune reconstitution in aged models', 'Thymic function modulation', 'Reported lifespan extension in animals']),
                'common_use_cases' => json_encode(['Immunosenescence research', 'Thymic peptide investigations', 'Aging biology studies']),
                'how_it_works' => 'Thymalin contains a complex of low-molecular-weight thymic peptides proposed to interact with chromatin and modulate gene expression in immune cells. The constituent peptides are reported to promote T-cell precursor differentiation, restore CD4/CD8 ratios, and support thymic microenvironment function in aging models.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 5. Fragment 176-191
            // ──────────────────────────────────────────────
            'fragment-176-191' => [
                'title' => 'Fragment 176-191',
                'peptide_full_name' => 'Human Growth Hormone Fragment 176-191',
                'research_title' => 'Fragment 176-191: A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of HGH Fragment 176-191, a modified C-terminal fragment of human growth hormone, examining its lipolytic mechanism, preclinical evidence in fat metabolism research, and current regulatory status.',
                'education_tag' => 'Metabolic Research',
                'description' => 'Fragment 176-191 (HGH Frag 176-191) is a synthetic peptide corresponding to the C-terminal region (amino acids 176-191) of human growth hormone, with a tyrosine substitution. It retains the lipolytic activity of full-length GH while lacking its growth-promoting and diabetogenic effects, making it a research tool for studying GH-mediated fat metabolism.',
                'molecular_formula' => 'C₇₈H₁₂₅N₂₃O₂₃S₂',
                'molecular_weight' => '1,817.1 g/mol',
                'half_life' => '15-30 minutes',
                'bioavailability' => 'Parenteral (short-acting peptide fragment)',
                'background' => 'Fragment 176-191 was developed based on the observation that the lipolytic activity of human growth hormone could be localized to a specific region of the GH molecule. Research by Ng and colleagues identified that the C-terminal domain of GH, specifically amino acids 176-191, retained fat-mobilizing properties independent of the growth-promoting and insulin-antagonizing effects associated with the full-length hormone. The synthetic peptide corresponding to this region, with a tyrosine modification to stabilize the molecule, demonstrated the ability to stimulate lipolysis in adipose tissue both in vitro and in vivo without affecting IGF-1 levels or glucose homeostasis. This dissociation of lipolytic from somatotropic activity made Fragment 176-191 an attractive research tool for studying the mechanisms of GH-mediated lipid metabolism. The peptide was further developed by Metabolic Pharmaceuticals (now Calzada Ltd.) in Melbourne, Australia, and entered early-stage clinical development (Phase 2 obesity trial under the code AOD-9604) before the program was discontinued. The peptide\'s mechanism is thought to involve mimicry of the GH interaction with a putative lipolytic receptor domain distinct from the canonical GH receptor.',
                'mechanism_of_action_intro' => 'Fragment 176-191 is hypothesized to stimulate lipolysis through a mechanism distinct from canonical GH receptor signaling, potentially involving direct interaction with adipocyte membrane components.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'Unlike full-length GH, Fragment 176-191 does not bind the classical GH receptor (GHR) and does not activate JAK2/STAT5 signaling responsible for IGF-1 production and growth effects.',
                        'points' => [
                            'Stimulates lipolysis in adipocytes through a mechanism independent of the canonical GH receptor (GHR)',
                            'Proposed to interact with a distinct adipocyte membrane domain or receptor that mediates GH\'s lipolytic action',
                            'Activates hormone-sensitive lipase (HSL) in adipose tissue, promoting triglyceride hydrolysis',
                            'Does not stimulate IGF-1 production, indicating no activation of the GHR/JAK2/STAT5 axis',
                            'Does not antagonize insulin action or impair glucose tolerance, unlike full-length GH',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Fragment 176-191 has been studied in cell culture systems, animal models, and a limited number of human trials (as AOD-9604), with research focused on lipolysis and body composition.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Lipolysis and Adipose Tissue Research',
                        'findings' => [
                            ['title' => 'In Vitro Lipolysis', 'description' => 'Studies using isolated rodent and human adipocytes demonstrated that Fragment 176-191 stimulates lipolysis at concentrations comparable to full-length GH, with a dose-dependent increase in glycerol release as a marker of triglyceride hydrolysis.'],
                            ['title' => 'Chronic Administration in Obese Models', 'description' => 'In ob/ob mice and diet-induced obesity models, chronic administration of Fragment 176-191 reduced body weight and fat mass without affecting food intake, lean mass, or IGF-1 levels, supporting a direct lipolytic mechanism.'],
                        ],
                    ],
                    [
                        'title' => 'Metabolic Safety Profile',
                        'findings' => [
                            ['title' => 'Glucose Homeostasis', 'description' => 'Unlike full-length GH, Fragment 176-191 did not impair glucose tolerance or insulin sensitivity in preclinical models, supporting the dissociation of lipolytic from diabetogenic GH effects.'],
                            ['title' => 'Growth and IGF-1 Independence', 'description' => 'Fragment 176-191 did not promote longitudinal growth in hypophysectomized rats and did not elevate serum IGF-1, confirming the absence of somatotropic activity.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'While preclinical data and limited clinical data (as AOD-9604) exist, Fragment 176-191 is not an approved therapeutic. The AOD-9604 clinical program was discontinued. All current use is for research purposes only.',
                'human_use_intro' => 'Fragment 176-191, under the development code AOD-9604, entered Phase 2 clinical trials for obesity conducted by Metabolic Pharmaceuticals in Australia.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Trial Data', 'entries' => [['type' => 'content', 'value' => 'A Phase 2a trial in obese subjects reported that AOD-9604 (oral formulation) was well-tolerated. Some treatment groups showed trends toward weight loss, though the trial did not meet its primary endpoint with statistical significance.'], ['type' => 'content', 'value' => 'The AOD-9604 clinical development program was discontinued by Metabolic Pharmaceuticals after Phase 2 results did not demonstrate sufficient efficacy for continued investment. The compound subsequently received TGA (Australia) approval as a food ingredient (GRAS-equivalent status) but not as a therapeutic agent.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Fragment 176-191 (AOD-9604) is not approved by the FDA or EMA as a therapeutic agent. The Australian TGA classified it as a food-grade ingredient, not a medicine.'], ['type' => 'content', 'value' => 'WADA has prohibited AOD-9604/Fragment 176-191 under the category of peptide hormones and growth factors. Research-grade products are sold for laboratory use only (RUO).']]]]),
                'regulatory_important_note' => 'Fragment 176-191 is an experimental research peptide. Its clinical development as a therapeutic was discontinued. It is not approved for human therapeutic use or self-administration.',
                'potential_applications_intro' => 'Based on preclinical evidence and discontinued clinical work, Fragment 176-191 research focuses on GH-mediated lipolysis mechanisms.',
                'potential_applications' => json_encode([
                    ['title' => 'GH Lipolysis Mechanism Research', 'description' => 'Fragment 176-191 is a unique tool for dissecting the lipolytic domain of GH independently of its growth-promoting and diabetogenic effects.'],
                    ['title' => 'Adipose Biology Studies', 'description' => 'The peptide enables investigation of GH-mediated lipid mobilization pathways in isolated adipocyte systems.'],
                    ['title' => 'Body Composition Research Models', 'description' => 'Preclinical data support its use in studying fat mass regulation independently of IGF-1 axis activation.'],
                ]),
                'potential_applications_important_context' => 'Clinical development was discontinued. All current applications are restricted to preclinical research. No therapeutic claims are made.',
                'conclusion' => 'Fragment 176-191 provides a unique pharmacological tool for studying the lipolytic domain of human growth hormone in isolation from its growth-promoting and metabolically adverse effects. The concept that GH\'s fat-mobilizing activity could be separated from its somatotropic and diabetogenic actions represents an important insight in endocrine pharmacology. Preclinical data consistently demonstrated fat mass reduction without effects on IGF-1, glucose tolerance, or lean mass. However, the clinical development program (as AOD-9604) was discontinued after Phase 2 trials failed to demonstrate robust efficacy in human obesity. This disconnect between preclinical and clinical outcomes underscores the challenges of translating peptide research into therapeutic applications. Fragment 176-191 continues to serve as a research tool for investigating GH-mediated lipolysis mechanisms and adipocyte biology, though its therapeutic development appears unlikely to resume.',
                'references' => json_encode([
                    ['title' => 'Obesity Research (2001)', 'authors' => 'Ng FM et al.', 'links' => []],
                    ['title' => 'Journal of Endocrinology (2000)', 'authors' => 'Ng FM, Bornstein J.', 'links' => []],
                    ['title' => 'Hormone and Metabolic Research (2004)', 'authors' => 'Heffernan MA et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Fragment 176-191 is the C-terminal lipolytic domain of human growth hormone', 'Stimulates lipolysis without affecting IGF-1, glucose tolerance, or growth', 'Phase 2 clinical development (as AOD-9604) was discontinued for insufficient efficacy', 'Available for research use only (RUO) — not an approved therapeutic']),
                'overview' => 'Fragment 176-191 is a synthetic peptide representing the lipolytic domain of human growth hormone, studied for its ability to promote fat metabolism independently of GH\'s somatotropic effects.',
                'areas_of_research_intro' => 'Fragment 176-191 research focuses on GH lipolysis mechanisms, adipose biology, and metabolic pharmacology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Lipid Metabolism', 'description' => 'GH-mediated lipolysis and adipocyte lipid mobilization'],
                    ['name' => 'Adipose Biology', 'description' => 'Fat mass regulation and adipocyte physiology'],
                    ['name' => 'Endocrine Pharmacology', 'description' => 'Dissociation of GH functional domains'],
                ]),
                'key_effects' => json_encode(['Stimulates lipolysis in adipose tissue', 'No effect on IGF-1 or growth', 'No impairment of glucose tolerance', 'Selective GH lipolytic domain action']),
                'common_use_cases' => json_encode(['Lipolysis mechanism research', 'Adipocyte biology studies', 'GH domain function investigations']),
                'how_it_works' => 'Fragment 176-191 mimics the C-terminal lipolytic domain of GH, stimulating hormone-sensitive lipase activity in adipocytes through a putative receptor mechanism distinct from the canonical GH receptor. It promotes triglyceride hydrolysis without activating the GHR/JAK2/STAT5 axis responsible for IGF-1 production and growth.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 6. Triptorelin
            // ──────────────────────────────────────────────
            'triptorelin' => [
                'title' => 'Triptorelin',
                'peptide_full_name' => 'Triptorelin (GnRH Agonist)',
                'research_title' => 'Triptorelin: A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of Triptorelin, a synthetic GnRH agonist with established clinical applications, examining its pharmacological mechanism, approved uses, preclinical and clinical evidence, and regulatory status.',
                'education_tag' => 'Reproductive Health',
                'description' => 'Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with a D-Trp substitution at position 6 that confers resistance to enzymatic degradation and enhanced receptor binding affinity. As a GnRH agonist, it initially stimulates and then suppresses the hypothalamic-pituitary-gonadal axis through receptor downregulation.',
                'molecular_formula' => 'C₆₄H₈₂N₁₈O₁₃',
                'molecular_weight' => '1,311.5 g/mol',
                'half_life' => '3-5 hours (immediate release); depot formulations extend to weeks',
                'bioavailability' => 'Parenteral (intramuscular or subcutaneous depot formulations)',
                'background' => 'Triptorelin was developed as part of a systematic effort to create GnRH analogs with improved pharmacokinetic properties compared to native GnRH. By substituting D-tryptophan at position 6 of the native GnRH decapeptide, researchers produced a compound with approximately 100-fold greater potency than natural GnRH and markedly increased resistance to enzymatic degradation by endopeptidases. The key pharmacological feature of triptorelin — and all GnRH agonists — is the paradoxical suppression effect: while acute administration stimulates gonadotropin (LH and FSH) release, continuous or depot administration causes GnRH receptor downregulation and desensitization of pituitary gonadotropes, resulting in profound suppression of sex steroid production (medical castration). This biphasic response — initial stimulation ("flare") followed by sustained suppression — is exploited clinically. Triptorelin has been approved in multiple countries under brand names including Trelstar, Decapeptyl, and Diphereline for indications including prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and as part of assisted reproductive technology protocols. It is one of the most widely used GnRH agonists in clinical medicine.',
                'mechanism_of_action_intro' => 'Triptorelin exerts its effects through binding to pituitary GnRH receptors (GnRHR). The distinction between pulsatile and continuous exposure determines whether it acts as a stimulant or suppressant of the HPG axis.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'As a super-potent GnRH agonist, triptorelin produces a characteristic biphasic response on the hypothalamic-pituitary-gonadal axis.',
                        'points' => [
                            'Binds GnRH receptors with ~100x greater affinity than native GnRH due to D-Trp6 substitution',
                            'Acute administration causes initial LH/FSH surge ("flare effect") and transient increase in testosterone/estrogen',
                            'Continuous or depot administration causes GnRH receptor downregulation and desensitization of gonadotropes',
                            'Sustained receptor downregulation results in profound suppression of LH, FSH, and gonadal sex steroid production (chemical castration)',
                            'Depot formulations provide sustained release over 1, 3, or 6 months, maintaining suppression without daily administration',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Triptorelin has been extensively studied in animal models and has a robust clinical evidence base supporting its approved therapeutic indications.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Reproductive Endocrinology Research',
                        'findings' => [
                            ['title' => 'HPG Axis Suppression', 'description' => 'In rodent and primate models, continuous triptorelin administration reliably suppresses gonadotropin secretion and reduces gonadal sex steroid levels to castrate range within 2-4 weeks, confirming the receptor downregulation mechanism.'],
                            ['title' => 'Reversibility', 'description' => 'Animal studies demonstrate that HPG axis suppression is reversible upon cessation of triptorelin, with recovery of gonadotropin pulsatility and gonadal function, though the timeline varies by duration of treatment.'],
                        ],
                    ],
                    [
                        'title' => 'Oncology Research',
                        'findings' => [
                            ['title' => 'Androgen-Dependent Tumor Models', 'description' => 'In prostate cancer xenograft models, triptorelin-mediated androgen deprivation significantly reduced tumor growth, consistent with the established role of androgen suppression in prostate cancer management.'],
                            ['title' => 'Direct Antiproliferative Effects', 'description' => 'Some in vitro studies suggest GnRH agonists may have direct antiproliferative effects on tumor cells expressing GnRH receptors, independent of their endocrine suppression mechanism. This remains an area of active investigation.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Triptorelin is an approved pharmaceutical with extensive clinical data. However, research-grade triptorelin is not equivalent to pharmaceutical preparations and is intended solely for laboratory research.',
                'human_use_intro' => 'Triptorelin is one of the most clinically well-established GnRH agonists, with multiple approved indications supported by extensive randomized controlled trials.',
                'human_use_subsections' => json_encode([
                    [
                        'title' => 'Approved Clinical Indications',
                        'entries' => [
                            ['type' => 'content', 'value' => 'Advanced prostate cancer: Triptorelin depot formulations (Trelstar, Decapeptyl) are approved for androgen deprivation therapy in hormone-sensitive prostate cancer, achieving castrate testosterone levels in over 90% of patients.'],
                            ['type' => 'content', 'value' => 'Endometriosis and uterine fibroids: Triptorelin is approved for the management of endometriosis-related pain and for preoperative reduction of uterine fibroid volume through estrogen suppression.'],
                            ['type' => 'content', 'value' => 'Central precocious puberty: Depot triptorelin is approved for treatment of central precocious puberty in children, suppressing premature activation of the HPG axis.'],
                            ['type' => 'content', 'value' => 'Assisted reproduction: Short-course triptorelin is used in IVF protocols to prevent premature LH surges during controlled ovarian stimulation.'],
                        ],
                    ],
                ]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Triptorelin is approved by the FDA (as Trelstar), EMA (as Decapeptyl/Diphereline), and numerous national regulatory agencies for multiple indications. It is a well-established pharmaceutical with decades of clinical use.'], ['type' => 'content', 'value' => 'Research-grade triptorelin is distinct from pharmaceutical preparations. It is sold for laboratory research purposes only (RUO) and is not suitable for human administration.']]]]),
                'regulatory_important_note' => 'Research-grade triptorelin is not equivalent to FDA/EMA-approved pharmaceutical triptorelin. It is sold for laboratory research purposes only and is not intended for human use.',
                'potential_applications_intro' => 'Triptorelin\'s clinical applications are well-established. Ongoing research explores additional contexts where HPG axis modulation may be relevant.',
                'potential_applications' => json_encode([
                    ['title' => 'Oncology Research', 'description' => 'Beyond prostate cancer, GnRH agonists are investigated in estrogen-dependent breast cancer and potential direct antitumor effects via tumor-expressed GnRH receptors.'],
                    ['title' => 'Reproductive Biology', 'description' => 'Triptorelin remains a tool for studying HPG axis dynamics, gonadotrope desensitization, and GnRH receptor pharmacology.'],
                    ['title' => 'Neuroendocrinology', 'description' => 'Research into GnRH receptor expression and function in extrapituitary tissues, including the central nervous system, continues to expand the scope of GnRH agonist research.'],
                ]),
                'potential_applications_important_context' => 'Triptorelin has established clinical uses in pharmaceutical form. Research-grade products are for laboratory use only and are not interchangeable with approved medications.',
                'conclusion' => 'Triptorelin is a paradigmatic example of rational peptide drug design, where a single amino acid substitution (D-Trp6) transformed native GnRH into a therapeutically powerful agonist with dramatically improved potency and metabolic stability. Its clinical applications in prostate cancer, endometriosis, precocious puberty, and assisted reproduction are supported by decades of randomized controlled trials and extensive post-marketing experience. The paradoxical suppression mechanism — where an agonist produces functional antagonism through receptor downregulation — remains one of the most elegant concepts in endocrine pharmacology. Triptorelin continues to serve as both a clinical therapeutic and a research tool for investigating GnRH receptor biology, HPG axis dynamics, and the broader pharmacology of receptor desensitization. Research-grade triptorelin is not equivalent to pharmaceutical preparations and is intended solely for laboratory investigation.',
                'references' => json_encode([
                    ['title' => 'The Lancet Oncology (2009)', 'authors' => 'Bentley P et al.', 'links' => []],
                    ['title' => 'European Journal of Endocrinology (2005)', 'authors' => 'Heger S et al.', 'links' => []],
                    ['title' => 'Journal of Clinical Oncology (2004)', 'authors' => 'Kaisary AV et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Triptorelin is a synthetic GnRH agonist with ~100x potency of native GnRH', 'Continuous administration causes HPG axis suppression via receptor downregulation', 'FDA/EMA-approved for prostate cancer, endometriosis, precocious puberty, and ART', 'Research-grade products are for laboratory use only (RUO)']),
                'overview' => 'Triptorelin is an approved GnRH agonist that suppresses the HPG axis through receptor downregulation, with established clinical use in oncology and reproductive medicine.',
                'areas_of_research_intro' => 'Triptorelin research spans oncology, reproductive endocrinology, and receptor pharmacology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Oncology', 'description' => 'Androgen deprivation therapy and direct antitumor GnRH effects'],
                    ['name' => 'Reproductive Medicine', 'description' => 'HPG axis modulation, ART protocols, and puberty research'],
                    ['name' => 'Receptor Pharmacology', 'description' => 'GnRH receptor desensitization and downregulation mechanisms'],
                ]),
                'key_effects' => json_encode(['Initial gonadotropin flare followed by suppression', 'Sustained chemical castration with depot forms', 'Reversible HPG axis suppression', 'Enhanced potency over native GnRH']),
                'common_use_cases' => json_encode(['GnRH receptor pharmacology research', 'HPG axis suppression studies', 'Reproductive endocrinology models']),
                'how_it_works' => 'Triptorelin binds pituitary GnRH receptors with ~100x the affinity of native GnRH. Acute exposure causes LH/FSH release. Continuous depot exposure causes receptor internalization, downregulation, and desensitization of gonadotropes, resulting in suppressed LH/FSH and castrate-level sex steroids.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 7. Thyrotropin-Releasing Hormone (TRH)
            // ──────────────────────────────────────────────
            'thyrotropin-trh' => [
                'title' => 'Thyrotropin-Releasing Hormone (TRH)',
                'peptide_full_name' => 'Thyrotropin-Releasing Hormone (Protirelin)',
                'research_title' => 'Thyrotropin-Releasing Hormone (TRH): A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of TRH, a hypothalamic tripeptide central to the hypothalamic-pituitary-thyroid axis, covering its neuroendocrine roles, CNS effects, diagnostic applications, and research significance.',
                'education_tag' => 'Neuroendocrinology',
                'description' => 'Thyrotropin-releasing hormone (TRH) is a tripeptide (pyroGlu-His-Pro-NH2) produced by the hypothalamus that stimulates the anterior pituitary to release thyroid-stimulating hormone (TSH) and prolactin. Beyond its endocrine role, TRH functions as a neurotransmitter/neuromodulator with widespread CNS distribution and diverse extrahypothalamic effects.',
                'molecular_formula' => 'C₁₆H₂₂N₆O₄',
                'molecular_weight' => '362.38 g/mol',
                'half_life' => '5-6 minutes',
                'bioavailability' => 'Parenteral (rapidly degraded by serum and tissue pyroglutamyl peptidases)',
                'background' => 'Thyrotropin-releasing hormone (TRH) was one of the first hypothalamic releasing hormones to be structurally characterized, identified independently by the groups of Roger Guillemin and Andrew Schally in 1969 — work that contributed to their shared Nobel Prize in 1977. TRH is a modified tripeptide (pyroGlu-His-Pro-NH2) with both N-terminal pyroglutamate and C-terminal amidation that protect against exopeptidase degradation. It is synthesized as a larger precursor (prepro-TRH) primarily in the paraventricular nucleus (PVN) of the hypothalamus and undergoes extensive post-translational processing. TRH released into the hypothalamic-hypophyseal portal circulation stimulates thyrotrope cells in the anterior pituitary to synthesize and secrete TSH, which in turn stimulates the thyroid gland. TRH also stimulates prolactin release from lactotrope cells. However, the biological significance of TRH extends far beyond the thyroid axis. TRH is widely distributed throughout the CNS — including brainstem, spinal cord, and cerebellum — where it functions as a neurotransmitter with effects on arousal, thermoregulation, gastric function, cardiovascular tone, and nociception. This dual identity as both a hypothalamic hormone and a CNS neuromodulator makes TRH a uniquely versatile research molecule.',
                'mechanism_of_action_intro' => 'TRH signals through two G-protein coupled receptors (TRH-R1 and TRH-R2) that activate phospholipase C signaling, with distinct distributions accounting for its endocrine and CNS effects.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'TRH receptor activation triggers Gq/11-coupled phosphoinositide signaling, leading to calcium mobilization and downstream cellular responses.',
                        'points' => [
                            'Binds TRH receptor type 1 (TRH-R1) on pituitary thyrotropes and lactotropes, activating PLC-IP3-DAG signaling and calcium-dependent TSH/prolactin release',
                            'TRH-R2, expressed primarily in the CNS, mediates non-endocrine neuromodulatory effects including arousal, thermoregulation, and gastric motility',
                            'Very short half-life (~5 minutes) due to rapid degradation by pyroglutamyl aminopeptidase II (PPII) in blood and tissues',
                            'Central TRH signaling modulates noradrenergic and serotonergic neurotransmission, contributing to its analeptic (arousal-promoting) properties',
                            'Negative feedback: thyroid hormones (T3/T4) suppress both TRH gene expression in the hypothalamus and thyrotrope responsiveness to TRH',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'TRH has been extensively studied in animal models and human clinical settings across both endocrine and CNS research domains.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Neuroendocrine Research',
                        'findings' => [
                            ['title' => 'HPT Axis Regulation', 'description' => 'TRH is the essential hypothalamic signal for maintaining the hypothalamic-pituitary-thyroid axis. Animal models with TRH gene deletion develop central hypothyroidism, confirming its non-redundant role.'],
                            ['title' => 'Prolactin Regulation', 'description' => 'TRH is a physiologically significant prolactin-releasing factor. In vitro and in vivo studies demonstrate dose-dependent prolactin release from lactotropes following TRH administration.'],
                        ],
                    ],
                    [
                        'title' => 'CNS Effects',
                        'findings' => [
                            ['title' => 'Analeptic and Arousal Effects', 'description' => 'Central TRH administration produces potent arousal, reversal of sedation, and respiratory stimulation in animal models. These effects are independent of thyroid hormone changes and are mediated by CNS TRH receptors.'],
                            ['title' => 'Thermoregulation', 'description' => 'Intracerebroventricular TRH produces hyperthermia in rodent models through activation of sympathetic thermogenesis, implicating TRH in central temperature regulation.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'TRH is well-characterized in both animal and clinical settings. Its diagnostic use (TRH stimulation test) has clinical precedent, but research-grade TRH is for laboratory use only.',
                'human_use_intro' => 'TRH (as protirelin) has an established clinical history as a diagnostic agent for evaluating pituitary TSH reserve via the TRH stimulation test.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Applications', 'entries' => [['type' => 'content', 'value' => 'The TRH stimulation test was a standard diagnostic tool in endocrinology for distinguishing hypothalamic from pituitary causes of hypothyroidism. Intravenous TRH (200-500 mcg) was administered, with TSH measured at baseline and at 20-30 minute intervals. The test has been largely supplanted by sensitive third-generation TSH assays.'], ['type' => 'content', 'value' => 'TRH (protirelin, Thypinone) was FDA-approved as a diagnostic agent. However, the pharmaceutical product was discontinued in many markets due to declining clinical use as TSH assays improved.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'TRH (protirelin) was FDA-approved as a diagnostic agent (Thypinone/Relefact TRH). The pharmaceutical product has been discontinued in many markets. Research-grade TRH is available for laboratory use only (RUO).'], ['type' => 'content', 'value' => 'TRH is not approved for therapeutic use. Its investigational use as a CNS-active agent for conditions such as depression, consciousness disorders, and spinal cord injury remains at the research stage.']]]]),
                'regulatory_important_note' => 'Research-grade TRH is not equivalent to pharmaceutical protirelin. It is sold for laboratory research purposes only and is not intended for human diagnostic or therapeutic use.',
                'potential_applications_intro' => 'TRH research extends beyond thyroid endocrinology into CNS pharmacology and neuroscience.',
                'potential_applications' => json_encode([
                    ['title' => 'Neuroendocrine Axis Research', 'description' => 'TRH remains fundamental to studying HPT axis regulation, TSH secretion dynamics, and thyroid hormone feedback mechanisms.'],
                    ['title' => 'CNS Pharmacology', 'description' => 'TRH\'s analeptic, thermoregulatory, and neuroprotective properties make it relevant to neuroscience research on arousal, consciousness, and neurological disorders.'],
                    ['title' => 'TRH Analog Development', 'description' => 'Metabolically stable TRH analogs are being developed to exploit CNS effects while overcoming the native peptide\'s extremely short half-life.'],
                ]),
                'potential_applications_important_context' => 'All research applications are investigational. Research-grade TRH is for laboratory use only.',
                'conclusion' => 'Thyrotropin-releasing hormone holds a distinguished position in neuroendocrinology as one of the first hypothalamic releasing factors to be characterized, contributing to a Nobel Prize and fundamentally reshaping understanding of brain-endocrine communication. Its simplicity as a tripeptide belies its biological complexity — TRH serves simultaneously as a hypothalamic hormone regulating thyroid function, a prolactin-releasing factor, and a CNS neurotransmitter with effects on arousal, thermoregulation, gastric function, and potentially neuroprotection. The clinical utility of the TRH stimulation test, while largely superseded by modern TSH assays, demonstrated the translational value of hypothalamic peptide research. Ongoing investigation into metabolically stable TRH analogs aims to separate the peptide\'s CNS effects from its endocrine actions, potentially opening therapeutic avenues for neurological and psychiatric conditions. TRH continues to serve as both a foundational molecule in endocrinology education and an active subject of neuroscience research.',
                'references' => json_encode([
                    ['title' => 'Science (1969)', 'authors' => 'Boler J, Enzmann F, Folkers K et al.', 'links' => []],
                    ['title' => 'Endocrine Reviews (2006)', 'authors' => 'Fekete C, Lechan RM.', 'links' => []],
                    ['title' => 'Pharmacology & Therapeutics (2010)', 'authors' => 'Gary KA et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['TRH is a hypothalamic tripeptide (pyroGlu-His-Pro-NH2) that stimulates TSH and prolactin release', 'Functions as both a pituitary-regulating hormone and a CNS neurotransmitter/neuromodulator', 'Was used clinically as a diagnostic agent (TRH stimulation test) before being superseded by sensitive TSH assays', 'Research-grade TRH is for laboratory use only (RUO)']),
                'overview' => 'TRH is a hypothalamic tripeptide that stimulates pituitary TSH and prolactin release and functions as a CNS neuromodulator with effects on arousal and thermoregulation.',
                'areas_of_research_intro' => 'TRH research spans neuroendocrinology, thyroid physiology, and CNS pharmacology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Neuroendocrinology', 'description' => 'HPT axis regulation, TSH secretion, and thyroid feedback'],
                    ['name' => 'CNS Pharmacology', 'description' => 'Arousal, thermoregulation, and neuroprotection'],
                    ['name' => 'Peptide Drug Design', 'description' => 'Metabolically stable TRH analog development'],
                ]),
                'key_effects' => json_encode(['Stimulates TSH and prolactin release', 'CNS arousal and analeptic effects', 'Thermoregulatory modulation', 'Very short half-life (~5 minutes)']),
                'common_use_cases' => json_encode(['HPT axis research', 'Neuroendocrine signaling studies', 'CNS neuropeptide investigations']),
                'how_it_works' => 'TRH binds TRH receptors (TRH-R1 on pituitary, TRH-R2 in CNS), activating Gq/11-coupled phospholipase C signaling. This generates IP3 and DAG, triggering calcium mobilization and PKC activation. In thyrotropes, this drives TSH exocytosis. In CNS neurons, it modulates noradrenergic and serotonergic transmission.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 8. Melanotan I (Afamelanotide)
            // ──────────────────────────────────────────────
            'melanotan-i' => [
                'title' => 'Melanotan I (Afamelanotide)',
                'peptide_full_name' => 'Afamelanotide ([Nle4, D-Phe7]-α-MSH)',
                'research_title' => 'Melanotan I (Afamelanotide): A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of Melanotan I (Afamelanotide), a synthetic melanocortin agonist, examining its mechanism of action at MC1R, photoprotection research, clinical development for erythropoietic protoporphyria, and regulatory status.',
                'education_tag' => 'Dermatology Research',
                'description' => 'Melanotan I, also known as Afamelanotide and [Nle4, D-Phe7]-α-MSH, is a synthetic tridecapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) with enhanced potency and metabolic stability. It acts as a non-selective melanocortin receptor agonist with primary activity at MC1R, stimulating eumelanin synthesis in melanocytes.',
                'molecular_formula' => 'C₇₈H₁₁₁N₂₁O₁₉',
                'molecular_weight' => '1,646.85 g/mol',
                'half_life' => '~30 minutes (subcutaneous)',
                'bioavailability' => 'Subcutaneous (implant formulation for clinical use)',
                'background' => 'Melanotan I was developed at the University of Arizona by Victor Hruby and colleagues in the 1980s as part of a systematic program to create superpotent melanocortin analogs. The parent molecule, α-MSH, is a 13-amino acid peptide derived from proopiomelanocortin (POMC) that stimulates melanogenesis through the melanocortin 1 receptor (MC1R). Native α-MSH has a very short half-life and limited potency. By introducing norleucine at position 4 (replacing methionine to prevent oxidation) and D-phenylalanine at position 7 (enhancing receptor binding and enzymatic resistance), Hruby created [Nle4, D-Phe7]-α-MSH — a molecule with dramatically improved potency and stability. Melanotan I was subsequently developed as Afamelanotide by Clinuvel Pharmaceuticals (Melbourne, Australia) for clinical application. The compound stimulates eumelanin production independently of UV exposure, providing photoprotection through increased melanin density. Clinuvel successfully brought Afamelanotide through clinical trials, culminating in EMA approval (as Scenesse) in 2014 for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) and FDA approval in 2019. Melanotan I is distinct from Melanotan II, which is a shorter cyclic heptapeptide with broader melanocortin receptor activity.',
                'mechanism_of_action_intro' => 'Melanotan I signals primarily through the melanocortin 1 receptor (MC1R) on melanocytes, activating intracellular signaling cascades that drive melanin biosynthesis.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'MC1R activation by Melanotan I triggers the cAMP/PKA/CREB/MITF signaling cascade, the master pathway regulating melanogenesis in melanocytes.',
                        'points' => [
                            'Binds MC1R (melanocortin 1 receptor) on epidermal melanocytes with high affinity, activating Gs-coupled adenylyl cyclase',
                            'Increases intracellular cAMP, activating PKA, which phosphorylates CREB transcription factor',
                            'CREB activation upregulates MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte gene expression',
                            'MITF drives transcription of melanogenic enzymes including tyrosinase, TRP-1, and TRP-2, promoting eumelanin (photoprotective brown/black pigment) synthesis',
                            'Eumelanin production occurs independently of UV exposure, providing photoprotection without sun damage as the stimulus',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Melanotan I has been extensively studied in both preclinical models and human clinical trials, culminating in regulatory approval for erythropoietic protoporphyria.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Melanogenesis and Photoprotection Research',
                        'findings' => [
                            ['title' => 'UV-Independent Tanning', 'description' => 'In vitro and in vivo studies confirmed that Melanotan I stimulates eumelanin synthesis in melanocytes independently of UV radiation. In human skin models and clinical studies, subcutaneous Melanotan I increased melanin density and skin pigmentation.'],
                            ['title' => 'DNA Damage Reduction', 'description' => 'Preclinical studies demonstrated that increased eumelanin density following Melanotan I treatment reduced UV-induced DNA damage (cyclobutane pyrimidine dimers) in skin, suggesting a photoprotective mechanism beyond visible tanning.'],
                        ],
                    ],
                    [
                        'title' => 'Erythropoietic Protoporphyria Research',
                        'findings' => [
                            ['title' => 'EPP Animal Models', 'description' => 'In models of protoporphyrin-mediated photosensitivity, melanin induction via MC1R agonism provided a measurable reduction in phototoxic responses, supporting the rationale for clinical development in EPP.'],
                            ['title' => 'Tolerability', 'description' => 'Preclinical toxicology studies supported the safety profile of Melanotan I at therapeutic exposures, enabling progression to human clinical trials.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Afamelanotide is an approved pharmaceutical (Scenesse) for a specific indication. Research-grade Melanotan I is not equivalent to the approved pharmaceutical product and is intended for laboratory research only.',
                'human_use_intro' => 'Afamelanotide (pharmaceutical Melanotan I) has undergone extensive clinical development and is approved for the prevention of phototoxicity in erythropoietic protoporphyria.',
                'human_use_subsections' => json_encode([
                    [
                        'title' => 'Approved Clinical Use',
                        'entries' => [
                            ['type' => 'content', 'value' => 'Afamelanotide (Scenesse) received EMA approval in 2014 and FDA approval in 2019 for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). It is administered as a subcutaneous implant that releases the peptide over approximately 60 days.'],
                            ['type' => 'content', 'value' => 'Phase III trials demonstrated that Afamelanotide significantly increased the duration of pain-free sun exposure in EPP patients, with a favorable safety profile. Common side effects included implant site reactions, nausea, and headache.'],
                        ],
                    ],
                    [
                        'title' => 'Investigational Studies',
                        'entries' => [
                            ['type' => 'content', 'value' => 'Clinuvel has investigated Afamelanotide in additional photosensitivity conditions including vitiligo (in combination with phototherapy), polymorphic light eruption, and solar urticaria, with varying degrees of clinical evidence.'],
                        ],
                    ],
                ]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Afamelanotide (Scenesse) is EMA-approved (2014) and FDA-approved (2019) for prevention of phototoxicity in EPP. It is a prescription medicine administered as a subcutaneous implant in authorized treatment centers.'], ['type' => 'content', 'value' => 'Research-grade Melanotan I is not equivalent to pharmaceutical Afamelanotide (Scenesse). Research-grade products are sold for laboratory investigation only (RUO) and are not approved for self-administration or cosmetic use.']]]]),
                'regulatory_important_note' => 'Research-grade Melanotan I is not equivalent to the FDA/EMA-approved product Scenesse (Afamelanotide). It is sold for laboratory research purposes only and is not intended for human use, cosmetic tanning, or self-administration.',
                'potential_applications_intro' => 'Beyond its approved EPP indication, Afamelanotide research extends to other photosensitivity conditions and melanocortin biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Photosensitivity Disorder Research', 'description' => 'Ongoing clinical trials investigate Afamelanotide in conditions including vitiligo repigmentation (combined with narrowband UVB), polymorphic light eruption, and solar urticaria.'],
                    ['title' => 'Melanocortin Receptor Pharmacology', 'description' => 'Melanotan I serves as a reference agonist for studying MC1R signaling, melanocyte biology, and the melanocortin system.'],
                    ['title' => 'Photoprotection and DNA Damage Prevention', 'description' => 'Research into UV-independent melanin induction as a strategy for reducing UV-induced DNA damage and potentially photocarcinogenesis.'],
                ]),
                'potential_applications_important_context' => 'Approved use is limited to EPP via the pharmaceutical product Scenesse. All other applications are investigational. Research-grade products are for laboratory use only.',
                'conclusion' => 'Melanotan I (Afamelanotide) represents a successful translation from basic melanocortin peptide chemistry to an approved pharmaceutical. The rational design of [Nle4, D-Phe7]-α-MSH at the University of Arizona created a superpotent, metabolically stable MC1R agonist that stimulates photoprotective eumelanin production independently of UV exposure. Clinuvel\'s clinical development program demonstrated meaningful clinical benefit in erythropoietic protoporphyria, leading to EMA and FDA approval as Scenesse. This makes Afamelanotide one of the few research peptides to achieve full regulatory approval. Ongoing research explores its utility in other photosensitivity conditions and broader melanocortin biology. It is critical to distinguish between the approved pharmaceutical product (Scenesse implant) and research-grade Melanotan I, which is intended solely for laboratory investigation and is not approved for cosmetic or self-administration purposes.',
                'references' => json_encode([
                    ['title' => 'Peptides (1980)', 'authors' => 'Sawyer TK, Sanfilippo PJ, Hruby VJ et al.', 'links' => []],
                    ['title' => 'New England Journal of Medicine (2015)', 'authors' => 'Langendonk JG et al.', 'links' => []],
                    ['title' => 'British Journal of Dermatology (2014)', 'authors' => 'Biolcati G et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Melanotan I ([Nle4, D-Phe7]-α-MSH) is a superpotent synthetic analog of α-MSH', 'Stimulates eumelanin synthesis via MC1R independently of UV exposure', 'As Afamelanotide (Scenesse), it is FDA/EMA-approved for erythropoietic protoporphyria', 'Research-grade products are for laboratory use only (RUO) — not for cosmetic use']),
                'overview' => 'Melanotan I (Afamelanotide) is a synthetic α-MSH analog that stimulates melanogenesis through MC1R, approved as Scenesse for erythropoietic protoporphyria and investigated for other photosensitivity conditions.',
                'areas_of_research_intro' => 'Melanotan I research spans dermatology, melanocortin pharmacology, and photoprotection science.',
                'areas_of_research' => json_encode([
                    ['name' => 'Dermatology', 'description' => 'Photosensitivity disorders, vitiligo, and photoprotection'],
                    ['name' => 'Melanocortin Biology', 'description' => 'MC1R signaling, melanocyte physiology, and melanogenesis'],
                    ['name' => 'Skin Cancer Prevention', 'description' => 'UV-independent melanin induction and DNA damage reduction'],
                ]),
                'key_effects' => json_encode(['Stimulates eumelanin synthesis', 'UV-independent photoprotection', 'MC1R agonism', 'Enhanced stability over native α-MSH']),
                'common_use_cases' => json_encode(['Melanocortin receptor research', 'Melanogenesis studies', 'Photoprotection investigations']),
                'how_it_works' => 'Melanotan I binds MC1R on melanocytes, activating Gs-coupled adenylyl cyclase signaling. Increased cAMP activates PKA, which phosphorylates CREB, upregulating MITF transcription factor. MITF drives expression of tyrosinase and related enzymes, promoting eumelanin biosynthesis independently of UV stimulation.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 9. AICAR
            // ──────────────────────────────────────────────
            'aicar' => [
                'title' => 'AICAR',
                'peptide_full_name' => '5-Aminoimidazole-4-Carboxamide Ribonucleoside (Acadesine)',
                'research_title' => 'AICAR: A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of AICAR, a cell-permeable AMPK activator and purine biosynthesis intermediate, examining its role as an exercise mimetic, metabolic effects, preclinical and clinical evidence, and regulatory status.',
                'education_tag' => 'Metabolic Research',
                'description' => 'AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also known as Acadesine) is a cell-permeable nucleoside analog that is phosphorylated intracellularly to ZMP (AICAR monophosphate), an AMP mimetic that activates AMP-activated protein kinase (AMPK). AICAR has been widely used as a pharmacological tool to study AMPK biology and has gained attention as a potential exercise mimetic.',
                'molecular_formula' => 'C₉H₁₄N₄O₅',
                'molecular_weight' => '258.23 g/mol',
                'half_life' => '~1.5-2 hours',
                'bioavailability' => 'Parenteral and oral (cell-permeable nucleoside analog)',
                'background' => 'AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a naturally occurring intermediate in the de novo purine biosynthesis pathway. As an endogenous metabolite, it is normally present at low concentrations in cells. When administered exogenously, AICAR enters cells via adenosine transporters and is phosphorylated by adenosine kinase to form ZMP (AICA-ribotide, also known as AICAR monophosphate). ZMP is a structural analog of AMP and activates AMP-activated protein kinase (AMPK) by mimicking AMP binding to the gamma regulatory subunit. AMPK is a master regulator of cellular energy homeostasis, often described as a cellular fuel gauge. When activated, AMPK switches on catabolic pathways (fatty acid oxidation, glucose uptake, autophagy) and switches off anabolic pathways (fatty acid synthesis, protein synthesis, gluconeogenesis). AICAR gained significant public attention following a landmark 2008 study by Narkar et al. in Cell, which demonstrated that AICAR treatment improved treadmill running endurance in sedentary mice by 44% without exercise training, leading to its characterization as an "exercise in a pill." AICAR was previously investigated clinically (as Acadesine) in cardiac surgery settings for myocardial protection, though this development did not progress to approval. It has also been investigated as a potential treatment for B-cell chronic lymphocytic leukemia.',
                'mechanism_of_action_intro' => 'AICAR activates AMPK indirectly through its intracellular metabolite ZMP, which mimics AMP at the regulatory gamma subunit of the AMPK heterotrimer.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'AMPK activation by ZMP triggers a coordinated metabolic shift toward energy-generating catabolic pathways and away from energy-consuming anabolic processes.',
                        'points' => [
                            'Enters cells via adenosine transporters and is phosphorylated by adenosine kinase to ZMP',
                            'ZMP binds the gamma subunit of AMPK, allosterically activating the kinase and protecting against dephosphorylation of Thr172 on the alpha subunit',
                            'AMPK activation stimulates fatty acid oxidation via phosphorylation and inactivation of ACC (acetyl-CoA carboxylase)',
                            'Promotes GLUT4 translocation and glucose uptake in skeletal muscle independently of insulin',
                            'Activates PGC-1α transcriptional program, promoting mitochondrial biogenesis and oxidative fiber type gene expression',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'AICAR has been extensively used as a pharmacological tool in metabolic research, with landmark studies in exercise physiology, diabetes, and cancer biology.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Exercise Mimetic Research',
                        'findings' => [
                            ['title' => 'Endurance Enhancement', 'description' => 'The 2008 Narkar et al. study in Cell demonstrated that 4 weeks of AICAR treatment (500 mg/kg/day) in sedentary mice increased treadmill running endurance by 44% and upregulated oxidative metabolism genes in skeletal muscle, establishing AICAR as a prototypical exercise mimetic.'],
                            ['title' => 'Metabolic Reprogramming', 'description' => 'AICAR treatment shifts skeletal muscle fiber type composition toward oxidative (slow-twitch) phenotypes and increases mitochondrial density, mimicking adaptations normally seen with endurance exercise training.'],
                        ],
                    ],
                    [
                        'title' => 'Metabolic Disease Models',
                        'findings' => [
                            ['title' => 'Insulin Sensitivity', 'description' => 'In rodent models of diabetes and obesity, chronic AICAR administration improved glucose tolerance, reduced hepatic glucose output, and enhanced peripheral insulin sensitivity through AMPK-mediated mechanisms.'],
                            ['title' => 'Lipid Metabolism', 'description' => 'AICAR treatment reduces circulating triglycerides and free fatty acids in preclinical models by stimulating fatty acid oxidation and inhibiting hepatic lipogenesis via ACC phosphorylation.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'AICAR has been extensively studied in preclinical settings and limited clinical trials. It is not approved for metabolic or exercise-related indications. Results from animal models may not translate to human outcomes.',
                'human_use_intro' => 'AICAR (as Acadesine) has been investigated in human clinical trials primarily in cardiac surgery and oncology settings, though it has not received regulatory approval.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Trial History', 'entries' => [['type' => 'content', 'value' => 'Acadesine was evaluated in Phase II/III clinical trials for reduction of perioperative myocardial ischemic events during coronary artery bypass graft (CABG) surgery. While showing trends toward benefit, the trials did not meet primary endpoints, and development for this indication was discontinued.'], ['type' => 'content', 'value' => 'Early-phase clinical studies investigated Acadesine in B-cell chronic lymphocytic leukemia (B-CLL), based on preclinical evidence of AMPK-dependent and -independent cytotoxicity in CLL cells. These studies demonstrated tolerability but have not advanced to registration.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'AICAR (Acadesine) is not approved by the FDA or EMA for any therapeutic indication. Clinical development programs in cardiac surgery and oncology have not progressed to regulatory approval.'], ['type' => 'content', 'value' => 'AICAR is prohibited by WADA as a metabolic modulator under the S4 category (hormone and metabolic modulators). Research-grade AICAR is sold for laboratory use only (RUO).']]]]),
                'regulatory_important_note' => 'AICAR is an experimental research compound. It is not approved for human therapeutic use, exercise enhancement, or self-administration. It is prohibited in competitive sport.',
                'potential_applications_intro' => 'Based on extensive preclinical evidence, AICAR research spans metabolic disease, exercise physiology, and AMPK biology.',
                'potential_applications' => json_encode([
                    ['title' => 'AMPK Biology Research', 'description' => 'AICAR remains the most widely used pharmacological AMPK activator in research, serving as a standard tool for studying AMPK-dependent metabolic pathways.'],
                    ['title' => 'Exercise Mimetic Research', 'description' => 'AICAR\'s ability to activate exercise-like transcriptional programs without physical activity makes it central to research on molecular mechanisms of exercise adaptation.'],
                    ['title' => 'Metabolic Disease Modeling', 'description' => 'Preclinical effects on glucose homeostasis, lipid metabolism, and insulin sensitivity make AICAR relevant to diabetes and obesity research.'],
                ]),
                'potential_applications_important_context' => 'All applications are investigational. AICAR is not approved for any therapeutic use. It is prohibited in competitive sport by WADA.',
                'conclusion' => 'AICAR occupies a central position in metabolic research as the prototypical pharmacological AMPK activator. Its ability to shift cellular metabolism toward catabolic, energy-generating pathways — mimicking key aspects of exercise physiology without physical exertion — has made it one of the most influential research tools in the field. The landmark demonstration that AICAR could enhance endurance in sedentary mice catalyzed an entire field of exercise mimetic research and raised fundamental questions about the molecular basis of exercise adaptation. However, AICAR\'s clinical development history illustrates the challenges of translating a valuable research tool into an approved therapeutic: cardiac surgery and oncology programs did not achieve regulatory success. AICAR remains a preclinical research compound, prohibited in competitive sport, and continues to be the standard pharmacological tool for investigating AMPK biology, metabolic regulation, and exercise physiology at the molecular level.',
                'references' => json_encode([
                    ['title' => 'Cell (2008)', 'authors' => 'Narkar VA et al.', 'links' => []],
                    ['title' => 'Journal of Biological Chemistry (2000)', 'authors' => 'Corton JM et al.', 'links' => []],
                    ['title' => 'Circulation (2003)', 'authors' => 'Mangano DT et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['AICAR is a cell-permeable nucleoside that activates AMPK via its metabolite ZMP', 'Demonstrated 44% endurance enhancement in sedentary mice (exercise mimetic)', 'Clinical development in cardiac surgery and oncology did not achieve approval', 'Prohibited by WADA — research use only (RUO)']),
                'overview' => 'AICAR is a cell-permeable AMPK activator widely used as a metabolic research tool and characterized as an exercise mimetic based on preclinical endurance enhancement findings.',
                'areas_of_research_intro' => 'AICAR research spans exercise physiology, metabolic disease, and fundamental AMPK biology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Exercise Physiology', 'description' => 'Exercise mimetic mechanisms and endurance gene programs'],
                    ['name' => 'Metabolic Research', 'description' => 'AMPK activation, glucose homeostasis, and lipid metabolism'],
                    ['name' => 'Cell Biology', 'description' => 'AMPK signaling, autophagy, and mitochondrial biogenesis'],
                ]),
                'key_effects' => json_encode(['AMPK activation via ZMP', 'Enhanced fatty acid oxidation', 'Improved glucose uptake', 'Mitochondrial biogenesis promotion']),
                'common_use_cases' => json_encode(['AMPK pathway research', 'Exercise mimetic studies', 'Metabolic regulation investigations']),
                'how_it_works' => 'AICAR enters cells via adenosine transporters and is phosphorylated to ZMP by adenosine kinase. ZMP mimics AMP at the AMPK gamma subunit, allosterically activating AMPK. Active AMPK phosphorylates ACC (stimulating fat oxidation), promotes GLUT4 translocation (glucose uptake), and activates PGC-1α (mitochondrial biogenesis).',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 10. VIP (Vasoactive Intestinal Peptide)
            // ──────────────────────────────────────────────
            'vip' => [
                'title' => 'VIP (Vasoactive Intestinal Peptide)',
                'peptide_full_name' => 'Vasoactive Intestinal Peptide',
                'research_title' => 'VIP (Vasoactive Intestinal Peptide): A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide with broad physiological roles, examining its vasodilatory, immunomodulatory, and neuroprotective mechanisms, clinical research, and current status.',
                'education_tag' => 'Neuropeptide Research',
                'description' => 'Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is widely distributed throughout the central and peripheral nervous systems and functions as a potent vasodilator, bronchodilator, immunomodulator, and neuroprotective agent through VPAC1 and VPAC2 receptor signaling.',
                'molecular_formula' => 'C₁₄₇H₂₃₈N₄₄O₄₃S',
                'molecular_weight' => '3,326.8 g/mol',
                'half_life' => '~1-2 minutes',
                'bioavailability' => 'Parenteral (extremely short half-life limits systemic delivery)',
                'background' => 'Vasoactive intestinal peptide was discovered in 1970 by Said and Mutt, who isolated it from porcine duodenum based on its potent vasodilatory activity. Despite its name suggesting a gastrointestinal origin, VIP was subsequently found to be widely expressed throughout the central and peripheral nervous systems, functioning primarily as a neuropeptide and neurotransmitter rather than a classical gut hormone. VIP belongs to the glucagon/secretin/PACAP superfamily and shares structural homology with PACAP (pituitary adenylate cyclase-activating polypeptide), secretin, and glucagon. VIP is co-localized with acetylcholine in parasympathetic neurons and serves as a non-adrenergic, non-cholinergic (NANC) neurotransmitter in many organ systems. Physiologically, VIP participates in smooth muscle relaxation, exocrine secretion, circadian rhythm regulation, immune modulation, and neuroprotection. VIP signals through two G-protein coupled receptors — VPAC1 and VPAC2 — which are expressed in virtually every organ system. The peptide\'s extremely short plasma half-life (1-2 minutes) due to rapid enzymatic degradation has been a major challenge for therapeutic development, driving research into stabilized analogs and alternative delivery systems.',
                'mechanism_of_action_intro' => 'VIP signals through VPAC1 and VPAC2 receptors, both Gs-coupled GPCRs that activate adenylyl cyclase and increase intracellular cAMP, with additional signaling through Gq and other pathways depending on tissue context.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'VPAC receptor activation by VIP triggers cAMP-dependent and -independent signaling cascades with diverse physiological consequences depending on tissue distribution.',
                        'points' => [
                            'Activates VPAC1 and VPAC2 receptors (Gs-coupled), increasing intracellular cAMP via adenylyl cyclase, with downstream PKA activation',
                            'Potent vasodilation through direct relaxation of vascular smooth muscle via cAMP/PKA-mediated reduction in intracellular calcium',
                            'Immunomodulatory effects include suppression of pro-inflammatory cytokines (TNF-α, IL-6, IL-12) and promotion of regulatory T-cell differentiation',
                            'Neuroprotective mechanisms involve upregulation of BDNF and other neurotrophic factors, anti-oxidant enzyme expression, and inhibition of microglial activation',
                            'Regulates circadian rhythms through VPAC2 signaling in the suprachiasmatic nucleus (SCN) of the hypothalamus',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'VIP has been studied across an extraordinarily broad range of biological systems, reflecting the ubiquitous distribution of its receptors and the peptide\'s pleiotropic physiological functions.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Immunomodulation Research',
                        'findings' => [
                            ['title' => 'Anti-Inflammatory Effects', 'description' => 'In multiple animal models of autoimmune and inflammatory disease (including experimental autoimmune encephalomyelitis, collagen-induced arthritis, and sepsis models), VIP administration reduced disease severity, suppressed pro-inflammatory cytokine production, and promoted regulatory immune responses.'],
                            ['title' => 'T-Cell Regulation', 'description' => 'VIP has been shown to promote the differentiation of regulatory T cells (Tregs) and Th2 polarization while suppressing Th1 and Th17 responses, suggesting a role in immune tolerance mechanisms.'],
                        ],
                    ],
                    [
                        'title' => 'Neuroprotection Research',
                        'findings' => [
                            ['title' => 'Neurodegenerative Disease Models', 'description' => 'In Parkinson\'s disease and Alzheimer\'s disease animal models, VIP and stabilized analogs have demonstrated neuroprotective effects, reducing neuronal loss and neuroinflammation through suppression of microglial activation and upregulation of neurotrophic factors.'],
                            ['title' => 'Circadian Biology', 'description' => 'VIP is essential for synchronizing circadian oscillations in the suprachiasmatic nucleus. VIP-deficient mice exhibit disrupted circadian rhythms, demonstrating its non-redundant role in biological timekeeping.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'VIP has extensive preclinical data across multiple biological systems. However, its extremely short half-life has limited clinical translation. Most findings are from animal models and require validation with stabilized analogs or novel delivery systems.',
                'human_use_intro' => 'Clinical research with VIP has been limited by its extremely short half-life. Some clinical investigations have been conducted in pulmonary and inflammatory conditions.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Research', 'entries' => [['type' => 'content', 'value' => 'Inhaled VIP has been investigated in small clinical studies for pulmonary arterial hypertension (PAH) and sarcoidosis, with early-phase data suggesting improvements in pulmonary hemodynamics and exercise capacity. However, larger confirmatory trials have not been completed.'], ['type' => 'content', 'value' => 'VIP deficiency has been identified in some patients with chronic inflammatory respiratory diseases. Research into VIP replacement or supplementation strategies is ongoing but remains at early stages of clinical investigation.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'VIP is not approved by the FDA or EMA for any therapeutic indication. Aviptadil, a synthetic VIP analog, received Emergency Use Authorization investigation during COVID-19 for ARDS, but full approval has not been granted.'], ['type' => 'content', 'value' => 'Research-grade VIP is sold for laboratory investigation only (RUO). It is not approved for human therapeutic use or self-administration.']]]]),
                'regulatory_important_note' => 'VIP is an experimental research peptide. It is not approved for human therapeutic use or self-administration. All research must comply with applicable regulatory frameworks.',
                'potential_applications_intro' => 'The breadth of VIP\'s physiological roles has generated research interest across multiple therapeutic areas.',
                'potential_applications' => json_encode([
                    ['title' => 'Immunology and Autoimmune Research', 'description' => 'VIP\'s anti-inflammatory and tolerogenic properties make it a target for investigating novel approaches to autoimmune disease modulation.'],
                    ['title' => 'Neuroscience and Neuroprotection', 'description' => 'Neuroprotective effects in preclinical neurodegeneration models support research into VIP-based strategies for neurodegenerative diseases.'],
                    ['title' => 'Pulmonary Medicine Research', 'description' => 'Vasodilatory and bronchodilatory properties underpin ongoing investigation into pulmonary hypertension and respiratory disease applications.'],
                    ['title' => 'Circadian Biology', 'description' => 'VIP\'s essential role in SCN circadian synchronization makes it central to chronobiology research.'],
                ]),
                'potential_applications_important_context' => 'All potential applications are investigational. VIP is not approved for any therapeutic use. Its extremely short half-life remains a major barrier to clinical development.',
                'conclusion' => 'Vasoactive intestinal peptide is one of the most pleiotropic neuropeptides known, with physiological roles spanning vasodilation, bronchodilation, immunomodulation, neuroprotection, circadian regulation, and gastrointestinal secretion. Its discovery in 1970 opened a major chapter in neuropeptide biology, and five decades of research have revealed an ever-expanding landscape of VIP functions mediated through the ubiquitously expressed VPAC1 and VPAC2 receptors. Preclinical data supporting anti-inflammatory and neuroprotective applications are compelling, particularly in models of autoimmune disease and neurodegeneration. However, VIP\'s extremely short plasma half-life (1-2 minutes) has been a persistent barrier to clinical translation, and no VIP-based therapeutic has achieved regulatory approval. The development of metabolically stable VIP analogs, novel delivery systems (including inhaled formulations), and the emerging understanding of VIP\'s role in immune tolerance continue to sustain research interest in this versatile neuropeptide.',
                'references' => json_encode([
                    ['title' => 'Annals of the New York Academy of Sciences (1988)', 'authors' => 'Said SI, Mutt V.', 'links' => []],
                    ['title' => 'Nature Reviews Immunology (2004)', 'authors' => 'Delgado M, Pozo D, Ganea D.', 'links' => []],
                    ['title' => 'Pharmacological Reviews (2007)', 'authors' => 'Harmar AJ et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['VIP is a 28-amino acid neuropeptide with vasodilatory, immunomodulatory, and neuroprotective properties', 'Signals through VPAC1 and VPAC2 receptors to activate cAMP/PKA signaling', 'Extremely short half-life (~1-2 minutes) limits clinical translation', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'VIP is a broadly distributed neuropeptide with pleiotropic effects on vascular, immune, neuronal, and circadian systems, signaling through VPAC1 and VPAC2 receptors.',
                'areas_of_research_intro' => 'VIP research spans immunology, neuroscience, pulmonary medicine, and chronobiology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Immunology', 'description' => 'Anti-inflammatory and tolerogenic immune modulation'],
                    ['name' => 'Neuroscience', 'description' => 'Neuroprotection, circadian regulation, and neurotransmission'],
                    ['name' => 'Pulmonary Research', 'description' => 'Vasodilation, bronchodilation, and pulmonary hypertension'],
                ]),
                'key_effects' => json_encode(['Potent vasodilation and bronchodilation', 'Anti-inflammatory cytokine suppression', 'Neuroprotection and neurotrophic support', 'Circadian rhythm synchronization']),
                'common_use_cases' => json_encode(['Neuropeptide signaling research', 'Immunomodulation studies', 'Circadian biology investigations']),
                'how_it_works' => 'VIP binds VPAC1 and VPAC2 receptors on target cells, activating Gs-coupled adenylyl cyclase to increase intracellular cAMP. cAMP/PKA signaling relaxes smooth muscle (vasodilation), suppresses NF-κB-driven inflammatory gene transcription, upregulates neurotrophic factors, and synchronizes circadian clock gene oscillation in the SCN.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 11. Gonadorelin (GnRH)
            // ──────────────────────────────────────────────
            'gonadorelin-gnrh' => [
                'title' => 'Gonadorelin (GnRH)',
                'peptide_full_name' => 'Gonadotropin-Releasing Hormone (GnRH)',
                'research_title' => 'Gonadorelin (GnRH): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Gonadorelin, a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone, covering its central role in the hypothalamic-pituitary-gonadal axis, clinical diagnostic applications, and research significance.',
                'education_tag' => 'Reproductive Health',
                'description' => 'Gonadorelin is a synthetic decapeptide structurally identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). It stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), functioning as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis.',
                'molecular_formula' => 'C₅₅H₇₅N₁₇O₁₃',
                'molecular_weight' => '1,182.29 g/mol',
                'half_life' => '2-4 minutes',
                'bioavailability' => 'Requires parenteral administration (very short half-life)',
                'background' => 'Gonadorelin is a synthetic peptide structurally identical to the naturally occurring gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). This decapeptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) was first characterized in 1971 by Nobel laureate Andrew Schally, a discovery that fundamentally advanced reproductive endocrinology. GnRH is produced primarily by approximately 1,000-1,500 specialized neurons in the hypothalamus, predominantly in the preoptic area and arcuate nucleus. These neurons exhibit coordinated pulsatile secretion, releasing GnRH into the hypothalamic-hypophyseal portal circulation in discrete pulses every 60-120 minutes. This pulsatile pattern is essential for normal reproductive function — the frequency and amplitude of GnRH pulses differentially regulate LH and FSH synthesis and release. Faster pulse frequencies favor LH secretion, while slower frequencies favor FSH. Continuous (non-pulsatile) GnRH exposure paradoxically suppresses gonadotropin release through receptor downregulation, a phenomenon exploited clinically by GnRH agonist drugs. Synthetic gonadorelin has been used clinically as a diagnostic agent (GnRH stimulation test) for evaluating pituitary gonadotrope function and as a therapeutic agent in pulsatile GnRH pump therapy for hypothalamic amenorrhea.',
                'mechanism_of_action_intro' => 'Gonadorelin exerts its effects through binding to GnRH receptors (GnRHR) on gonadotrope cells in the anterior pituitary gland. The pattern of exposure — pulsatile versus continuous — critically determines the physiological response.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The GnRH receptor is a G-protein coupled receptor that uniquely lacks a C-terminal intracellular tail, which influences its desensitization and internalization kinetics.',
                        'points' => [
                            'Pulsatile GnRH administration mimics physiological secretion and maintains/stimulates gonadotropin (LH and FSH) release from pituitary gonadotropes',
                            'Continuous GnRH exposure causes receptor downregulation, internalization, and desensitization, leading to paradoxical suppression of LH/FSH (the basis for GnRH agonist therapeutics)',
                            'Activates Gq/11-coupled phospholipase C signaling, generating IP3 and DAG, triggering calcium mobilization from ER stores and calcium influx through L-type channels',
                            'Calcium/calmodulin-dependent exocytosis of LH and FSH secretory granules follows receptor activation',
                            'Very short half-life (2-4 minutes) due to rapid enzymatic cleavage by endopeptidases, principally between positions 5-6 and 9-10 of the decapeptide',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Gonadorelin has been studied extensively in animal models and human clinical settings over five decades, making it one of the most thoroughly characterized peptide hormones.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Reproductive Endocrinology Research',
                        'findings' => [
                            ['title' => 'HPG Axis Regulation', 'description' => 'Gonadorelin reliably stimulates LH and FSH release in a dose-dependent and species-conserved manner across all mammalian species tested. It remains the definitive pharmacological tool for studying HPG axis dynamics.'],
                            ['title' => 'Pulsatility and Differential Gonadotropin Regulation', 'description' => 'Foundational research demonstrated that GnRH pulse frequency differentially regulates LH versus FSH production — high frequency favors LH-beta gene expression, while low frequency favors FSH-beta — providing the basis for understanding differential gonadotropin secretion.'],
                        ],
                    ],
                    [
                        'title' => 'Receptor Pharmacology',
                        'findings' => [
                            ['title' => 'Receptor Downregulation', 'description' => 'Continuous GnRH exposure studies elucidated the mechanism of receptor downregulation and desensitization, directly informing the development of GnRH agonist therapeutics (leuprolide, goserelin, triptorelin) for prostate cancer, endometriosis, and precocious puberty.'],
                            ['title' => 'Self-Priming Effect', 'description' => 'Research demonstrated that prior GnRH exposure enhances pituitary responsiveness to subsequent pulses (self-priming), a mechanism important for the preovulatory LH surge and a key concept in reproductive physiology.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Gonadorelin is one of the most well-characterized peptide hormones with extensive clinical data. However, research-grade gonadorelin is intended solely for laboratory investigation and is not equivalent to pharmaceutical preparations.',
                'human_use_intro' => 'Gonadorelin has well-established clinical applications as a diagnostic agent and has been used therapeutically in pulsatile delivery for reproductive disorders.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Applications', 'entries' => [['type' => 'content', 'value' => 'Gonadorelin (as Factrel) was FDA-approved as a diagnostic agent for evaluating pituitary gonadotrope function via the GnRH stimulation test. Intravenous gonadorelin administration with timed LH/FSH measurements distinguishes hypothalamic from pituitary causes of hypogonadism.'], ['type' => 'content', 'value' => 'Pulsatile GnRH pump therapy (Lutrepulse) was approved and used clinically for the treatment of hypothalamic amenorrhea and hypogonadotropic hypogonadism, delivering physiological GnRH pulses to restore normal gonadotropin secretion and fertility. This approach demonstrated the clinical translation of GnRH pulsatility research.'], ['type' => 'content', 'value' => 'Gonadorelin is also used in veterinary medicine for reproductive management, including induction of ovulation in cattle, horses, and other species.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Gonadorelin has been approved in pharmaceutical forms (Factrel for diagnosis, Lutrepulse for pulsatile therapy) in various markets, though some products have been discontinued. Research-grade gonadorelin is not equivalent to pharmaceutical preparations and is sold for laboratory research only (RUO).'], ['type' => 'content', 'value' => 'Gonadorelin is listed by WADA as a prohibited substance in the peptide hormones category due to its ability to stimulate endogenous testosterone production via LH release.']]]]),
                'regulatory_important_note' => 'Research-grade gonadorelin is not equivalent to pharmaceutical gonadorelin products. It is sold for laboratory research purposes only and is not intended for human diagnostic, therapeutic, or self-administration purposes.',
                'potential_applications_intro' => 'Gonadorelin research spans reproductive endocrinology, neuroendocrinology, and receptor pharmacology.',
                'potential_applications' => json_encode([
                    ['title' => 'HPG Axis Physiology Research', 'description' => 'Gonadorelin remains the standard tool for studying pulsatile gonadotropin release, HPG axis feedback, and reproductive neuroendocrine function.'],
                    ['title' => 'Pituitary Function Assessment', 'description' => 'GnRH stimulation testing protocols continue to be refined for research into pituitary reserve and hypogonadism classification.'],
                    ['title' => 'Reproductive Pharmacology', 'description' => 'Understanding GnRH receptor dynamics — including self-priming, desensitization, and differential gonadotropin regulation — informs the development of next-generation GnRH agonists and antagonists.'],
                ]),
                'potential_applications_important_context' => 'Research-grade gonadorelin is for laboratory investigation only. Clinical applications require pharmaceutical-grade preparations under appropriate medical supervision.',
                'conclusion' => 'Gonadorelin stands as one of the most consequential discoveries in reproductive endocrinology. The structural characterization of GnRH by Andrew Schally — recognized with the Nobel Prize — revealed the hypothalamic peptide that orchestrates the entire reproductive hormone cascade. Five decades of subsequent research have illuminated how a single decapeptide, through the elegance of pulsatile secretion, differentially controls two distinct gonadotropins and thereby the full spectrum of gonadal function. The discovery that continuous GnRH exposure paradoxically suppresses the axis it normally stimulates led directly to an entire class of GnRH agonist drugs now used worldwide. Synthetic gonadorelin continues to serve as both a clinical diagnostic tool and a foundational research compound for investigating reproductive physiology, neuroendocrine signaling, and GPCR pharmacology. Research-grade gonadorelin remains strictly for laboratory investigation and is not equivalent to approved pharmaceutical preparations.',
                'references' => json_encode([
                    ['title' => 'Science (1971)', 'authors' => 'Schally AV et al.', 'links' => []],
                    ['title' => 'Endocrine Reviews (1997)', 'authors' => 'Conn PM, Crowley WF.', 'links' => []],
                    ['title' => 'New England Journal of Medicine (1986)', 'authors' => 'Crowley WF et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Gonadorelin is a synthetic decapeptide identical to endogenous GnRH, the master regulator of the HPG axis', 'Pulsatile administration stimulates LH/FSH; continuous exposure paradoxically suppresses via receptor downregulation', 'Has established clinical history as a diagnostic agent (Factrel) and pulsatile therapeutic (Lutrepulse)', 'Research-grade products are for laboratory use only (RUO)']),
                'overview' => 'Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH) that controls pituitary gonadotropin release and is central to reproductive endocrinology research.',
                'areas_of_research_intro' => 'Gonadorelin research spans reproductive endocrinology, neuroendocrinology, and GPCR pharmacology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Reproductive Endocrinology', 'description' => 'HPG axis regulation, gonadotropin pulsatility, and fertility'],
                    ['name' => 'Neuroendocrinology', 'description' => 'Hypothalamic peptide signaling and pituitary function'],
                    ['name' => 'Receptor Pharmacology', 'description' => 'GnRH receptor dynamics, desensitization, and self-priming'],
                ]),
                'key_effects' => json_encode(['Stimulates LH and FSH release (pulsatile)', 'Paradoxical suppression (continuous)', 'Very short half-life (2-4 minutes)', 'Differential gonadotropin regulation by pulse frequency']),
                'common_use_cases' => json_encode(['HPG axis research', 'Gonadotropin signaling studies', 'Reproductive physiology and pharmacology']),
                'how_it_works' => 'Gonadorelin binds GnRH receptors on anterior pituitary gonadotrope cells, activating Gq/11-coupled phospholipase C signaling. This generates IP3 and DAG, triggering calcium mobilization and PKC activation, leading to exocytosis of LH and FSH secretory granules. Pulsatile exposure sustains receptor expression and gonadotropin release; continuous exposure causes receptor internalization and HPG axis suppression.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 12. FOXO4-DRI
            // ──────────────────────────────────────────────
            'foxo4-dri' => [
                'title' => 'FOXO4-DRI',
                'peptide_full_name' => 'FOXO4-D-Retro-Inverso Peptide',
                'research_title' => 'FOXO4-DRI: A Comprehensive Research Overview',
                'research_outline' => 'An in-depth analysis of FOXO4-DRI, a D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells, examining its senolytic mechanism, preclinical findings in aging research, and current investigational status.',
                'education_tag' => 'Aging Research',
                'description' => 'FOXO4-DRI is a D-retro-inverso (DRI) peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. By interfering with this survival mechanism specific to senescent cells, FOXO4-DRI selectively induces apoptosis in senescent cells while sparing non-senescent cells, functioning as a targeted senolytic agent.',
                'molecular_formula' => 'D-amino acid peptide (~4,900 g/mol)',
                'molecular_weight' => '~4,900 g/mol',
                'half_life' => 'Extended (D-amino acid composition confers protease resistance)',
                'bioavailability' => 'Parenteral (D-retro-inverso design enhances stability)',
                'background' => 'FOXO4-DRI emerged from research by Peter de Keizer and colleagues at Erasmus University Medical Center in Rotterdam, published in Cell in 2017. The work addressed a central problem in aging biology: senescent cells — cells that have irreversibly exited the cell cycle in response to damage — accumulate with age and secrete a complex mixture of pro-inflammatory cytokines, chemokines, and proteases known as the senescence-associated secretory phenotype (SASP). This SASP contributes to chronic inflammation, tissue dysfunction, and age-related pathology. While senescent cells resist apoptosis through multiple mechanisms, de Keizer\'s group identified that the FOXO4-p53 interaction is a critical survival mechanism specific to senescent cells. In senescent cells, FOXO4 sequesters p53 in PML nuclear bodies, preventing p53 from triggering apoptosis at the mitochondria. The researchers designed FOXO4-DRI — a D-retro-inverso peptide that mimics a segment of FOXO4 — to competitively disrupt this interaction. D-retro-inverso peptides use D-amino acids in reversed sequence to maintain side-chain topology while conferring resistance to proteolytic degradation. By displacing p53 from FOXO4 sequestration, FOXO4-DRI allows p53 to translocate to the cytoplasm and activate the intrinsic apoptotic pathway, selectively eliminating senescent cells. This targeted approach distinguishes FOXO4-DRI from broad-spectrum senolytics like dasatinib and navitoclax.',
                'mechanism_of_action_intro' => 'FOXO4-DRI functions by disrupting a specific protein-protein interaction (FOXO4-p53) that maintains the viability of senescent cells, thereby selectively triggering apoptosis in the senescent cell population.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The senolytic mechanism of FOXO4-DRI is based on the observation that senescent cells depend on FOXO4-mediated p53 sequestration for survival, a dependency not present in non-senescent cells.',
                        'points' => [
                            'In senescent cells, FOXO4 is upregulated and physically sequesters p53 within PML (promyelocytic leukemia) nuclear bodies, preventing p53-mediated apoptosis',
                            'FOXO4-DRI competitively binds p53, displacing it from FOXO4 sequestration in PML bodies',
                            'Released p53 translocates from the nucleus to the cytoplasm, where it activates the mitochondrial (intrinsic) apoptotic pathway',
                            'Mitochondrial outer membrane permeabilization (MOMP) triggers caspase cascade and selective apoptosis of the senescent cell',
                            'Non-senescent cells do not depend on FOXO4-p53 interaction for survival, conferring selectivity to the senolytic effect',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'FOXO4-DRI has been studied in cell culture systems and aged mouse models, with the foundational 2017 Cell publication providing the primary preclinical evidence base.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Senescent Cell Clearance',
                        'findings' => [
                            ['title' => 'In Vitro Senolysis', 'description' => 'FOXO4-DRI selectively induced apoptosis in senescent human fibroblasts (IMR90 cells) and other senescent cell types in vitro while showing minimal toxicity to non-senescent proliferating cells. Cell viability assays demonstrated significant dose-dependent senolytic activity.'],
                            ['title' => 'Selectivity', 'description' => 'Comparative studies showed that FOXO4-DRI exhibited preferential toxicity toward senescent versus non-senescent cells, consistent with the proposed mechanism of disrupting a senescence-specific survival pathway.'],
                        ],
                    ],
                    [
                        'title' => 'In Vivo Aging Models',
                        'findings' => [
                            ['title' => 'Naturally Aged Mice', 'description' => 'In the de Keizer 2017 study, FOXO4-DRI treatment of fast-aging (XpdTTD/TTD) and naturally aged mice resulted in restoration of fur density, improved renal function (reduced plasma creatinine), and increased exploratory behavior. These phenotypic improvements were associated with reduced senescent cell markers in treated tissues.'],
                            ['title' => 'Chemotherapy-Induced Senescence', 'description' => 'In mice with doxorubicin-induced senescence, FOXO4-DRI administration reduced senescent cell burden and partially restored organ function, demonstrating utility in a therapy-induced senescence model.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from a single research group\'s publications using cell culture and mouse models. FOXO4-DRI has not been evaluated in human clinical trials. Independent replication and human translation are essential before drawing conclusions about therapeutic potential.',
                'human_use_intro' => 'No human clinical trials have been conducted with FOXO4-DRI. All evidence is preclinical, derived primarily from the original 2017 Cell publication and subsequent follow-up studies by the de Keizer laboratory.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'FOXO4-DRI has not entered human clinical trials. No IND applications are publicly registered. The compound remains in the early preclinical research stage. Human pharmacokinetics, safety, immunogenicity, and efficacy are entirely unknown.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'FOXO4-DRI is not approved by the FDA, EMA, or any regulatory body for human use. It is an early-stage research compound available for laboratory investigation only.'], ['type' => 'content', 'value' => 'As a D-amino acid peptide, FOXO4-DRI presents unique regulatory considerations including potential immunogenicity, tissue distribution, and long-term accumulation that would require thorough evaluation in formal preclinical development.']]]]),
                'regulatory_important_note' => 'FOXO4-DRI is an early-stage experimental research compound. It is not approved for human use, anti-aging applications, or self-administration. All current evidence is preclinical and from a single research group.',
                'potential_applications_intro' => 'FOXO4-DRI has generated significant interest in the senolytic and aging research communities based on its novel mechanism of targeted senescent cell elimination.',
                'potential_applications' => json_encode([
                    ['title' => 'Senolytic Research', 'description' => 'FOXO4-DRI provides a mechanistically distinct approach to senescent cell clearance compared to small-molecule senolytics, enabling comparative studies of senolytic strategies.'],
                    ['title' => 'Aging Biology', 'description' => 'As a tool for selective senescent cell ablation, FOXO4-DRI enables research into the causal role of senescent cell accumulation in age-related tissue dysfunction.'],
                    ['title' => 'SASP and Inflammation Research', 'description' => 'Selective elimination of SASP-producing senescent cells with FOXO4-DRI allows investigation of the contribution of the senescence-associated secretory phenotype to chronic inflammation and tissue pathology.'],
                ]),
                'potential_applications_important_context' => 'All potential applications are based on early-stage preclinical research. FOXO4-DRI has not been tested in humans. No therapeutic claims are made. Independent replication of foundational findings is ongoing.',
                'conclusion' => 'FOXO4-DRI represents one of the most mechanistically elegant approaches in the emerging senolytic field. By targeting a specific protein-protein interaction (FOXO4-p53) that maintains senescent cell viability, it offers a rationally designed strategy for selective senescent cell elimination without the broader cytotoxic effects associated with some small-molecule senolytics. The preclinical data from the de Keizer laboratory — showing restoration of fitness, fur density, and renal function in aged mice — are compelling and have generated substantial interest in the aging research community. However, important caveats apply. The evidence base is currently narrow, originating primarily from a single research group. No human data exist, and fundamental questions about immunogenicity, biodistribution, tissue penetration, and long-term safety of a D-retro-inverso peptide in mammals remain unanswered. FOXO4-DRI should be viewed as a valuable early-stage research tool for investigating the biology of cellular senescence and the potential of targeted senolysis, rather than as a near-term therapeutic candidate.',
                'references' => json_encode([
                    ['title' => 'Cell (2017)', 'authors' => 'Baar MPA, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourber BRM, Stryber S, Rijksen YMA, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WFJ, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ.', 'links' => []],
                    ['title' => 'Trends in Molecular Medicine (2017)', 'authors' => 'de Keizer PLJ.', 'links' => []],
                ]),
                'key_points' => json_encode(['FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells', 'Selectively induces apoptosis in senescent cells while sparing non-senescent cells', 'Preclinical data in aged mice showed restored fitness and organ function markers', 'Early-stage research compound — not approved for human use (RUO)']),
                'overview' => 'FOXO4-DRI is a rationally designed senolytic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 survival interaction.',
                'areas_of_research_intro' => 'FOXO4-DRI research is centered in the senolytic and aging biology fields.',
                'areas_of_research' => json_encode([
                    ['name' => 'Senolytic Research', 'description' => 'Targeted senescent cell clearance and comparison with other senolytic strategies'],
                    ['name' => 'Aging Biology', 'description' => 'Senescent cell contribution to age-related pathology and tissue dysfunction'],
                    ['name' => 'Cell Biology', 'description' => 'FOXO4-p53 interaction, PML body biology, and apoptosis regulation'],
                ]),
                'key_effects' => json_encode(['Selective senescent cell apoptosis', 'Disruption of FOXO4-p53 interaction', 'Protease resistance (D-amino acids)', 'Spares non-senescent cells']),
                'common_use_cases' => json_encode(['Senolytic mechanism research', 'Cellular senescence studies', 'Aging intervention investigations']),
                'how_it_works' => 'FOXO4-DRI is a D-retro-inverso peptide that mimics a segment of FOXO4 and competitively binds p53, displacing it from FOXO4 sequestration in PML nuclear bodies. In senescent cells — which depend on this FOXO4-p53 interaction for survival — the freed p53 translocates to the cytoplasm and activates the mitochondrial apoptotic cascade, selectively triggering cell death.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],
        ];
    }
}
